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ABSTRACT OF THE DISSERTATION
Engineering Poly(ethylene glycol) Materials to Promote Cardiogenesis
by
Amanda Walker Smith
Doctor of Philosophy in Biomedical Engineering
Washington University in St. Louis, 2013
Professor Donald L. Elbert, Committee Chair

Heart failure is one of the leading causes of death worldwide, and the current
costs of treatment put a significant economic burden on our societies. After an infarction,
fibrotic tissue begins to form as part of the heart failure cascade. Current options to slow
this process include a wide range of pharmaceutical agents, and ultimately the patient
may require a heart transplant. Innovative treatment approaches are needed to bring
down costs and improve quality of life. The possibility of regenerating or replacing
damaged tissue with healthy cardiomyocytes is generating considerable excitement, but
there are still many obstacles to overcome. First, while cell injections into the
myocardium have demonstrated slight improvements in cardiac function, the actual
engraftment of transplanted cells is very low. It is anticipated that improving engraftment
will boost outcomes. Second, cellular differentiation and reprogramming protocols have
not yet produced cells that are identical to adult cardiomyocytes, and immunogenicity
continues to be a problem despite the advent of autologously derived induced pluripotent
stem cells. This dissertation will explore biomaterials approaches to addressing these two
obstacles.

x

Tissue engineering scaffolds may improve cell engraftment by providing
bioactive factors, preventing cell anoikis, and reducing cell washout by blood flow.
Poly(ethylene glycol) (PEG) is often used as a coating to reduce implant rejection
because it is highly resistant to protein adsorption. Because fibrosis of a material in
contact with the myocardium could cause arrhythmias, PEG materials are highly relevant
for cardiac tissue engineering applications. In Chapter 2, we describe a novel method for
crosslinking PEG microspheres around cells to form a scaffold for tissue engineering.
We then demonstrate that HL-1 cardiomyocyte viability and phenotype are retained
throughout the fabrication process and during the first 7 weeks of culture.
In the third chapter of the dissertation, we demonstrate that the use of PEG cell
culture substrates can improve efficiency of direct reprogramming from fibroblasts to
cardiomyocytes for cell transplantation. Standard tissue culture plastic adsorbs proteins
from the cell media, increasing experimental variability via non-specific signaling.
Because of its protein resistant properties, PEG provides cells with highly specific signals.
In addition to improving the efficiency, we found that presentation of RGD peptides
stimulated proliferation during reprogramming. Combined, the improvements enabled us
to approximately double the number of cardiomyocytes produced by the protocol.
In Chapter 4, we explore the effects of 3D culture on the direct reprogramming
protocol described in Chapter 3. We demonstrate that the variables involved in 3D
culture, including scaffold material, diffusion, cellular remodeling, and scaffold
topography, have significant effects on reprogramming efficiency. This chapter provides
the groundwork for future studies developing 3D microenvironments for efficient and
scalable reprogramming to cardiomyocytes.
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CHAPTER 1
Introduction
1.1 The role of biomaterials in cardiac tissue
engineering
Nearly a hundred years ago, Ross Harrison, a Yale zoologist who is often
considered to be the “father of tissue culture” (1), noticed that environmental stimuli were
commonly reported to affect developing tissues, whether it be fish embryo
chromatophores responding to circulating blood (2) or nerve guidance by chemotactic

A

B

Figure 1.1: Early examples of materials used in cell culture. A) cells migrating out from embryos onto
spiderwebs, adapted from Harrison, 1914. B) Stretching fibrin clots was known to induce cell
elongation (adapted from Weiss, 1952)
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factors (3). In his own lab, he had noticed that cells embedded in firmly clotted lymph
took on a more migratory phenotype than those suspended in unclotted lymph droplets.
This made him curious about the effects of physical stimuli cell phenotype. In his 1914
paper, “The reaction of embryonic cells to solid structures” he describes diligently
collecting Tegenaria spiders from “old tree stumps” to create webs upon which he could
culture embryonic cell clusters. In perhaps the first description of cellular reactions to
culture materials, Harrison reported that spider webs provided paths for “cell wandering”,
or migration along the web (4) (Fig. 1a).
Tissue culture was founded by growing three-dimensional (3D) explants or
embryos in lymph or fibrin (5). However, 2D protocols were widely adopted by the field
in the 1920s, after Warren and Margaret Lewis developed them in order to investigate the
morphological details and compartments of single cells (6). These protocols allowed for
easier visualization of cellular responses, and also gave scientists greater control over
many variables (which will be discussed in Chapter 1.2 and Chapter 4). Recognizing the
importance of cellular interactions with the extracellular environment, Paul Weiss reintroduced the fibrin clot culture protocols in the 1950s . In a particularly notable
experiment, he described the tendency of cells to elongate in response to stretching the
fibrin substrate (Fig. 1b) (7).
In the 1970s, multiple groups noticed that when dissociated cardiac harvests were
reaggregated into 3D structures, they bore a closer resemblance to native tissue (8, 9). In
1977, Horres, Lieberman and Purdy engineered a 3D preparation with high mechanical
integrity by culturing the cells onto nylon fibers (10). This work, which was inspired by
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a need for easier “experimental manipulation” from 3D preparations, may mark the
introduction of the “synthetic scaffold” to the field of cardiac tissue engineering (CTE).
Heart failure is one of the largest public health problems, and will ultimately
affect 20% of Americans who are currently forty years old (11). Age-related fibrosis
around the sinoatrial node is another major health concern (12-16). Pharmaceutical
agents are the most common treatment, and in the worst case scenario a patient may be
placed on a wait list for a heart transplant. However, the drugs may have serious side
effects, and mortality rates on the transplant list hover around 10% per year (17). Over
the past 30 years, research in the field of CTE has developed with the goal of fully
repairing or replacing diseased myocardium. Research in this area usually takes one of
four forms; 1) injection of cells expected to provide therapeutic benefit to the damaged
area, 2) implantation of in vitro engineered cardiac tissue (often called a cardiac patch) to
either replace the infarct zone or support it from the outer surface, 3) in vivo genetic
alterations to return cells to cardiac phenotypes, or 4) introducing materials to induce
resident stem cell homing. Materials engineering principles are being applied in all of
these research areas. I will discuss the first and second in some detail. The third and
fourth are beyond the scope of this dissertation, but the reader can find thorough reviews
elsewhere (genetic manipulation: (18-20), stem cell homing: (21, 22)). For both cell
injections and engineered tissue implants, a major decision is the type of cell to use.

1.2 Cardiac cell sourcing
1.2.1 Pluripotent stem cell derived cardiomyocytes
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The ability to expand mouse embryonic stem cells (mESCs) in vitro (23, 24) was
the 1981 milestone that ignited the field of regenerative medicine. It provided a platform
for researchers to unravel embryonic development mechanisms and a hope of ultimately
engineering tissue replacements. Within 4 years, Doetschman et al. described the
differentiation of mESCs to cardiomyocytes (mESC-CMs) (25). However, it would be
nearly 20 years before human ESCs could be expanded in culture (26) and differentiated
to cardiomyocytes (27), highlighting major differences between the species. Nonetheless,
murine stem cell studies continue to provide preliminary research that jump-starts human
cell research.
In addition to ethical concerns, a major obstacle for ESC-derived transplants is the
potential for immune rejection due to their allogenic origin. In 2006 and 2007,
Yamanaka and colleagues introduced the induced pluripotent stem cell (iPSC), providing
a less contentious, autologous, and (presumably) safer alternative. Human and mouse
iPSCs are generated by activating a combination of four transcription factors (collectively
called the Yamanaka factors) (28, 29), which induce epigenetic changes to reset the
genetic expression profile of the cell (30). Using the knowledge gained from ESC studies,
several groups quickly demonstrated that mouse and human iPSCs could be differentiated
to cardiomyocytes by similar protocols (31-34). In 2007, LaFlamme et al. described a
growth factor based protocol that drastically increased efficiency of cardiomyocyte
derivation to ~30% (35). More recently, small molecule differentiation has been shown
to promote cardiogenesis with 98% efficiency (36), providing a cheaper, more efficient,
and more stable alternative to growth factor based protocols.
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While iPSCs initially seemed like the perfect alternative to ESCs, recent studies
have found that the two may not be as similar as originally thought. Derivatives of both
cell types carry carcinogenic risk unless they are immaculately purified (37, 38), and at
least one group has reported that iPSC cells develop into more aggressive tumors than
ESCs (39). Unlike ESCs, iPSCs are sourced from adult somatic cells, which may have
accumulated mutations over time. The reprogramming process also introduces new
opportunities for genetic errors. Mutations resulting in uncontrolled proliferation and
resistance to apoptosis (tumorogenic qualities) are evolutionarily favorable traits within
the reprogramming cell population (40, 41), which may explain why mutations at known
oncogenic genes are more common in iPSCs (42) . These errors are in addition to genetic
aberrations that appear with repeat passaging, as is seen with hESCs (43-46). Errors that
occur during reprogramming may help to explain a surprising recent study that found
iPSCs to be immunogenic in syngenic hosts (47). Another problem with iPSCs is
“epigenetic memory”, or remnants of epigenetic modifications from the original cell (4850). Cells with epigenetic memory show differentiation biases toward the germ layer of
the cell source (51).
A recent study by Newman and Cooper (52) reanalyzed gene expression data
from seven different laboratories that had previously compared iPSCs to ESCs. Many of
these groups had reported distinct differences between the two cell types, but the
differences found were not consistent between labs. Newman et al. performed a
computational meta-analysis of the data. They determined that gene expression
signatures were strongly correlated with the laboratory of origin, calling the previous
conclusions into question. They wrap up the paper with a call to consider the effects of
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the microenvironment on reprogramming processes. In chapter 1.2, I will discuss how
materials can be used to control microenvironmental variables.
Despite the obstacles, in vivo studies in small mammals have demonstrated
modest improvements after injection of pluripotent-cell derived cardiomyocytes (35, 53,
54) or even undifferentiated pluripotent cells (55, 56). Actual cell engraftment is quite
low, suggesting that the benefits are likely related to paracrine effects (35, 57). Due to
the hurdles outlined above, the progress of large animal in vivo studies has been slow,
especially when considering that human trials of adult stem cells injections are well under
way (58). However, the potential for unlimited expansion of pluripotent stem cells
necessitates that we continue to explore this area of research, as the sheer number of cells
needed for these types of therapies is quite large (59).

1.2.2 Adult stem cell derived cardiomyocytes
While embryonic and induced pluripotent stem cells have the capacity for greater
scalability, many groups are studying adult stem cell techniques due to the concerns
outlined above. This area of research is quite broad, and generally beyond the scope of
this dissertation. However, the field merits some discussion since several human trials
are already underway, many showing modest improvements in cardiac function (34, 58,
60). The majority of groups working with adult derived stem cells are using bone
marrow derived mesenchymal stem cells (MSCs). When Orlic et al. (61) and Strauer et
al. (62) first provided evidence that MSCs induced myocardial regeneration and
functional improvement in 2001, it was unclear if the benefits were related to true
differentiation of the MSCs to cardiomyocytes, or to some other effects (63, 64). This
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controversy has still not been fully settled (58, 65). However, since actual stem cell
engraftment is low (~5%) (66, 67), most groups now agree that increased vascularization
(68) and paracrine signals from the transplanted MSCs play a much larger role (58, 69)
than any differentiation. One such paracrine mechanism may be the activation of resident
adult cardiac stem cells (CSCs), which normally play only a minor role in cardiac
regeneration (70). Interestingly, CSCs themselves can be harvested, expanded in vitro
(71, 72), and injected back into damaged myocardium. Cardiac ejection fraction (a
common and useful functional endpoint, meaning the volumetric fraction that the heart
pumps out during contraction) has been improved in a number of studies in different
animal models. As with MSCs, these improvements appear to be more closely related to
paracrine signaling since CSC engraftment is low (73). While studies are promising, the
clinical adoption of this cell source will likely require functional improvements of a much
higher magnitude (58).

1.2.3 Direct reprogramming
Direct reprogramming protocols are a recent addition to the list of potential
cardiomyocyte sources, and have generated much excitement over the past few years.
Direct reprogramming (also referred to as direct conversion or transdifferentiation) refers
to a phenotypical switch that does not involve going through the pluripotent state, and has
been reported for multiple different lineages (recently reviewed by Morris et al. (74)). In
2010, Ieda et al. first reported direct reprogramming of mouse fibroblasts to
cardiomyocytes using a combination of transcription factors (Gata4, Mef2c, and Tbx5)
crucial to cardiac development (75), and several variations of that protocol have since
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been published (76, 77). The conversion of fibroblasts to iPSC is usually on the range of
1% (78), and cardiac differentiation efficiency from there is as high as 98% (36), giving
an overall fibroblast to cardiomyocyte efficiency of about 1%. Ieda et al. reported higher
efficiency conversions (~5% troponin-T positive) of fibroblasts directly to
cardiomyocytes by 4-5 weeks (75), as opposed to ~6-7 weeks for fibroblast to iPSC to
cardiomyocyte derivations (36, 79).
Potentially the most exciting application of this research is the potential to
reprogram scar tissue fibroblasts to cardiomyocytes in vivo, potentially negating the need
for cell transplants. This has been demonstrated in small mammals by multiple groups
(77, 80-82), one that used micro-RNAs (1, 133, 208, and 499) instead of the transcription
factors (82). Up until recently, all research has been performed using mouse somatic
cells. In March of 2013, the first article reporting direct reprogramming of adult human
fibroblasts to cardiomyocytes was published online (83), confirming the potential for
clinical use. This protocol used a combination of transcription factors (Gata4, Hand2,
Tbx5 and Myocardin) in addition to miRNAs-1 and -133.
Less than a year after the first report of direct reprogramming to cardiomyocytes,
the Deng group demonstrated that similar results could be achieved using a
fundamentally different method. Efe et al. briefly activated the Yamanaka factors
(normally used to generate iPSCs) to push cells into an epigenetically unstable state,
while simultaneously inhibiting pluripotentcy pathways (84). After 9 days, they
introduced BMP4 to stimulate cardiogenesis. By day 18, they reported widespread
beating and ~40% troponin-T positive cells. During the process, they did note a small
population of pluripotent cells, but demonstrated that these cells were not the source of
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the cardiomyocytes. Instead, the pathway led through a proliferative progenitor state that
is known to also produce cardiac vasculature (84, 85).
The protocol described by Efe et al. is faster than the one by Ieda et al., which
may be clinically important as the cardiac remodeling cascade starts immediately
following infarction (86, 87). The possibility of forming the other myocardial cell types
is a huge advantage, as revascularization will be important to myocardial scar healing.
Several groups have noted the improvements in cardiomyocyte organization in vitro (88)
and cardiac function in vivo when a vascular system is also provided within the construct
at implantation (“prevascularization”) (89, 90). Further characterization of this protocol
is needed to quantify endothelial and smooth muscle cells differentiation efficiency.
Despite the advantages listed above, excitement for the Efe et al. protocol is
tempered by the formation of pluripotent byproducts (Nanog levels were low but
detectable by day 18 (84)). This teratoma risk will have to be eliminated before any
human trials could take place. Unlike other protocols, it has not yet been replicated with
human cells, or shown to work in vivo. Furthermore, all direct reprogramming protocols
may encounter the same “epigenetic memory” problems that have plagued iPSC research.
Nonetheless, this area of research is growing and advancing quickly (91), and these
hurdles may soon be irrelevant. Further detail and discussion of direct reprogramming
can be found in chapter 3 of this dissertation.

1.3 Materials for stem cell microenvironment
engineering
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The meta-analysis that found gene expression of reprogrammed cells to correlate
strongly with the lab of origin (52) elucidated the effects of the microenvironment on
stem cell research. The “microenvironment” can encompass a wide range of variables,
including oxygen levels, temperature, pH, and media components. However, one that
often goes unappreciated in stem cell research is the culture surface, which in reality
should be broken down into several additional variables. Cell adhesion to the
extracellular matrix (ECM) is accomplished through cell-surface integrins that link to the
cytoskeleton (92, 93). Cytoskeleton-mediated intracellular pathways may then affect cell
phenotype, making ECM-integrin interactions important to differentiation and
reprogramming (94-99). Cellular phenotype can be affected by ECM protein types (100),
spacing (7, 101) and concentrations (102), as well as substrate topography (103-107)
mechanical properties (108, 109), and cell shape (110, 111).
While these factors are known to have profound effects on stem cells (100, 112),
the majority of differentiation and reprogramming studies still use tissue culture
polystyrene (TCPS) as the cell culture substrate. The topographical and mechanical
features of TCPS (flat and stiff) may be sub-optimal for differentiation to many cell types.
For example, in Engler et al., mesenchymal stem cells cultured on very hard substrates
preferred osteogenic differentiation, whereas those cultured on softer substrates preferred
myogenic or neurogenic pathways (112). To provide a closer mimic the natural
environment, ECM proteins are often electrostatically adsorbed to the TCPS prior to cell
seeding. However, proteins from serum in the media may also adsorb, and these may
activate non-specific intracellular pathways that vary by serum batch. While the
breakneck speed of stem cell advances makes it inconvenient to question long-established
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methods, true therapeutic value has not yet been realized. Innovative approaches are
needed to increase the value of stem cell research.
Multiple examples exist in the literature where engineering the stem cell
microenvironment has changed differentiation patterns. In 2004, McBeath et al.
demonstrated that the size of “cell islands” (micropatterned ECM) affected the extent of
hMSC spreading, which in turn dictated their differentiation to either adipocytes (small
islands) or osteoblasts (large islands). They determined that the cytoskeletal shape
affected the RhoA pathway, which in turn affected the differentiation (110). Later, Kilian
et al. demonstrated that cell shape still affected hMSC differentiation even if the
patterned area (and therefore, number of cell-to-ECM contacts) was held constant (111).
Nanotopography has shown to dictate differentiation outcomes to neural (104) or
osteogenic (105) phenotypes, likely by changes in cytoskeletal organization (101, 113).
In addition to the role of substrate stiffness on hMSC differentiations (112), mESCs may
also be affected by substrate stiffness, with softer substrates being better suited for the
maintenance of pluripotency (114). Studies with hESCs have recently shown that culture
under biaxial strain helps to maintain pluripotency via the TGFβ-Activin-Nodal pathway
(99, 115).
In addition to the effects of ECM composition, stiffness, topography and other
mechanical factors, natural stem cell niches are 3D environments. Culture in 2D forces
cell polarity, changes the membrane-to-cytoplasm ratio, and alters the cell shape (116),
all of which have physiological repercussions (110, 111, 117, 118). This might help to
explain drastic phenotypical differences that are often seen between 2D and 3D cultured
cells (119-123). Schenke-Layland et al. recently demonstrated that designing 3D stem
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cell culture to mimic in vivo CSC niches improved differentiation from mESCs to cardiac
progenitors (124). However, variations cannot be attributed solely to differences in
dimension, since 3D environments incorporate all of the variables mentioned above, as
well as diffusion limitations not present in 2D culture. Nonetheless, 3D environments
more closely mimic natural environments, while simultaneously addressing scalability
problems encountered with 2D culture (59). Further discussion on 3D stem cell culture,
as well as additional examples from the literature, can be found in Chapter 4 of this
dissertation.

1.4 Using materials to improve cell engraftment in vivo
As mentioned previously, clinical trials of MSC injections have yielded only
modest improvements (0-5% increase in ejection fraction) (125-128), and only ~5% of
cells are actually engrafting into the myocardium (66, 67). Anoikis, or apoptosis
resulting from lack of adhesion, is a likely reason for this problem (129). Laflamme et al.
found that including Matrigel during injection to prevent anoikis of hESC-CMs helps to
improve engraftment and functional outcomes (35). Similarly, Kutschka et al. found that
delivery of cardiomyocytes to rat infarcts using collagen-Matrigel composites improved
cell engraftment and ejection fraction over injections alone (130). Zimmermann et al.
demonstrated similar effects when suturing a cardiomyocyte-loaded collagen gel on the
surface of infarcted hearts (131).
In addition to anoikis, other reasons that transplanted cells are lost are 1) they are
killed going through the needle, 2) they cannot survive the ischemic environment, 3) they
are killed by reactive oxygen species (ROS) secreted by inflammatory cells that are
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responding to the infarction, or 4) they are washed out by circulation. Materials are being
developed to address these issues, as well. For example, Aguado et al. demonstrated that
cells encapsulated within a highly compliant alginate hydrogel during injection had a
higher rate of survival (132). To combat ischemia, many groups have focused on
“prevascularizing” the graft, or including a ready-made capillary network. In one
example, cardiomyocyte sheets were fabricated with or without endothelial cells and
fibroblasts. The inclusion of endothelial cells enabled perfusion by the host vasculature
and improved graft survival (89). Simultaneous delivery of superoxide dismutase, a
superoxide scavenger, can reduce cell death due by ROS (133). Delivery of this unstable
enzyme can be improved by encapsulating it in polyketal microspheres (134).
Injection of in situ polymerizing hydrogels alone (without cells) may also
improve functional outcomes (135-137), possibly by providing structural support,
releasing bioactive factors, or recruiting endogenous CSCs (138). Because cells are not
involved, human clinical trials are farther along (139). However, the addition of cells
within materials remains a promising area of research, since they provide functional
improvements over materials alone in small animal models (130, 137, 140). The major
challenges are 1) optimizing cell sourcing, 2) ensuring electrical and mechanical coupling
with the myocardium, and 3) vascularizing constructs to improve graft viability (141).
Another hurdle to this area of research is difficulty in comparing results between
studies. Because the field has developed so recently, preparation protocols, delivery
methods, animal models, and functional endpoints are still highly variable between
research groups (141). Also, studies often focus on one specific material instead of
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comparing several (138), making it difficult to determine which will ultimately perform
best.

1.5 Poly(ethlyene glycol) biomaterials for cardiac tissue
engineering
Poly(ethylene glycol) (PEG) has been described as a “stealth material” and has
long been approved by the FDA for clinical use (142). Because of its resistance to
protein adsorption and cell adhesion, PEG is a highly favored material for many
therapeutic applications. Here, I will discuss its potential in stem cell niche engineering
and myocardial cell transplantations.

1.5.1 History of PEG materials
Over long periods of time, most materials adsorb proteins from the blood,
triggering the foreign body response that walls off the implant in a fibrotic capsule (143).
PEG was first reported to prevent cell adhesion during coagulation studies in the early
1970s (144). Furasawa et al. later demonstrated that including PEG in copolymers
decreased protein adsorption (145), which was confirmed by Brash, Whicher, and Uniyal
(146, 147). A few years later, it was found that platelet adhesion was lower on PEG
surfaces than on PVP surfaces (148). Considering results from his own lab (149-151) in
conjunction with various results from other labs, Merrill composed a convincing
argument that PEG may be one of the least thrombogenic materials available (152). 	
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These findings supporting PEG as a nonthrombogenic material set off a wave of
research into “PEGylation” of previously studied materials, as well as investigation into
PEG-copolymers. In 1994, Hill-West et al. demonstrated that balloon angioplastyinduced restenosis could be nearly eliminated by coating the surface of the treated artery
with PEG-diacrylate (153). In 1993, Hubbell and colleagues developed a PEGpolylactide surgical sealant to use as a preventative measure against adhesions that
frequently occur as a result of certain surgical procedures (154). While these performed
relatively well in small animals, results in humans were more difficult to assess.
However, the sealant has been adapted for use in lung (155) and brain (156) surgeries.

1.5.2 PEG for engineering the stem cell niche
As mentioned previously, the majority of stem cell research studies have utilized
tissue culture polystyrene (TCPS) as the culture substrate. In addition to being a poor
reproduction of the in vivo environment, TCPS adsorbs proteins from the serum,
presenting cells with non-specific signals that may vary by serum batch. Because of its
protein-resistant properties, PEG is an excellent candidate substrate for stem cell research
studies (157) because it provides a silent “background” for probing the effects of other
molecules (158). In addition, PEG can be tuned to adjust the matrix stiffness (159),
incorporate bioactive moieties (160-162), and degrade at a controlled pace (163), all of
which can affect stem cell differentiation outcomes (112, 164). Recently, Lutolf and
colleagues have developed a high throughput method to investigate several of these
variables simultaneously in 2D using a PEG microwell array (165). The Khademhosseini
and Hubbell groups have recently published interesting studies of cardiac differentiation
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from embryoid bodies embedded in PEG gels (159, 166). Further discussion on using
PEG materials to engineer the stem cell niche can be found in chapter 3 of this
dissertation.

1.5.3 PEG for myocardial cell transplantation
Of the synthetic materials available, PEG is one of the least likely to cause protein
adsorption and fibrosis. For cardiac tissue engineering, this is highly important as
fibrosis could lead to arrhythmias and death. Most materials used so far in the cardiac
setting are degradable to ensure a limited foreign body response. The Suggs group has
developed an injectable PEGylated fibrin material for use in cardiac repair (167). This
hybrid material provides dual benefits of natural and synthetic materials: the fibrin
provides topographical cues, degradation, and adhesion sites, while the PEG acts as a
spacer molecule to enhance cell viability and also provides an inert vehicle for delivering
growth factors (167). When delivered via injection, the MSC-loaded PEGylated fibrin
group had the highest ejection fraction after 4 weeks (as opposed to PEGylated fibrin
without cells or cells injected alone) (140).
The Hubbell group has developed injectable matrix metalloproteinase sensitive
PEG hydrogels for myocardial repair. In a recent study, these were loaded with hESCderived endothelial and smooth muscle cells to provide paracrine benefits and
vascularization potential, without the complications of electrically and mechanically
integrating cardiomyocytes (137). They saw improvements in ejection fraction at 6
weeks in a rat myocardial infarction model. The highest performing group had been
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treated with a cell-loaded gel that also included thymosin β4, a pro-angiogenic survival
factor. This was significantly higher than improvements made by the gel alone (168).
A recent study by Wu et al. reports low cytotoxicity of a supramolecular PEGbased hydrogel that incorporates poly(caprolactone) for degradation and α-cyclodextrin
for enhanced drug delivery (169). Four weeks after injection into a rabbit myocardial
infarction, control groups (injection of DMEM alone) demonstrated a 30.3% decrease in
ejection fraction. MSC injection alone demonstrated a significant improvement over the
control (17.5% decrease, up 12.8% from control), but injection of MSC loaded gels
performed the best (6.8% decrease, up 23.5% from control) (170). The delivery of
erythropoietin (EPO) from the hydrogels improved outcomes over EPO injections alone
and hydrogel injections alone (171).
Several other groups have also recently published in vivo studies analyzing the
protective effects of PEG hydrogels after myocardial infarction (172-174), and at this
point the number of potentially useful strategies (biocompatible material X cell source X
drug to be delivered) seems limitless. A common theme is that the most improvement
comes when cells are delivered within a hydrogel. PEG gels alone do not present the
same level of improvements in the studies described above or in recent publications by
Rane et al. (173) and Dobner et al. (174). The next decade of research in CTE involving
cell transplantation will need to focus on starting human trials to test these strategies.
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CHAPTER 2*
Long term culture of HL-1 cardiomyocytes in
modular poly(ethylene glycol) microsphere-based
scaffolds crosslinked in the phase separated state
2.1 Abstract
Poly(ethylene glycol) (PEG) microspheres were assembled around HL-1
cardiomyocytes to produce highly porous modular scaffolds. In this study, we took
advantage of the immiscibility of PEG and dextran to improve upon our previously
described modular scaffold fabrication methods. Phase separating the PEG microspheres
in dextran solutions caused them to deswell and crosslink together rapidly, eliminating
the need for serum protein-based crosslinking. This also led to a dramatic increase in the
stiffness of the scaffolds and greatly improved the handling characteristics. HL-1
cardiomyocytes were present during the microsphere crosslinking in the cytocompatible
dextran solution, exhibiting high cell viability following scaffold formation. Over the
course of 2 weeks, a 9-fold expansion in cell number was observed. The cardiac
functional markers sarcomeric α-actinin and connexin 43 were expressed at 13 and 24
days after scaffold formation. HL-1 cells were spontaneously depolarizing 38 days after
scaffold formation, which was visualized by confocal microscopy using a calciumsensitive dye. Electrical stimulation resulted in synchronization of activation peaks
*

Chapter 2 has been adapted from the following manuscript:
Smith AW, Segar CE, Nguyen PK, MacEwan MR, Efimov IR, Elbert DL. Long-term
culture of HL-1 cardiomyocytes in modular poly(ethylene glycol) microsphere-based
scaffolds crosslinked in the phase-separated state. Acta Biomaterialia. Jan 2012. 8(1):3140
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throughout the scaffolds. These findings demonstrate that PEG microsphere scaffolds
fabricated in the presence of dextran can support the long-term three-dimensional culture
of cells, suggesting applications in cardiovascular tissue engineering.

2.2 Introduction
Advancements in cardiac tissue engineering (CTE) are currently limited by a
number of engineering challenges. Engineered myocardium must contain a dense
population of properly aligned and electrically connected cardiomyocytes. Scaffold
materials must be extremely resistant to foreign body reaction because fibrous
encapsulation might electrically isolate the engineered tissue and cause arrhythmias.
Cardiomyocytes are highly metabolically active, form a well-coupled electromechanical
syncytium, and must be in intimate contact with the vascular system (175, 176).
Scaffolds may also need to be highly porous to allow passage of nutrients so that cells
survive even at the center of a large construct (177-179).
Most methods for producing porous scaffolds utilize processing conditions that
are not compatible with cell survival. Consequently, cells must be seeded onto the
exterior of a pre-formed scaffold. However, this may result in uneven cell distribution
unless steps are taken to promote deeper cell penetration (180-183). To achieve well
distributed cell density, cytocompatible crosslinking and pore formation techniques may
be needed. Bulk poly(ethylene glycol) (PEG) hydrogels are easily formed in the presence
of cells with high cell viability (184-186). However, the porosity of these scaffolds is at
the nanoscale and methods to introduce pores are usually not cytocompatible (187-189).
A different approach is the formation of cell scaffolds by crosslinking hydrogel
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microparticles in the presence of cells. This technique introduces pores between the
microparticles, which may provide greater nutrient diffusion and pathways for cells to
migrate and proliferate. Sefton and colleagues have encapsulated cardiomyocytes and
other cells in collagen-based modules, which were then coated with endothelial cells.
The modules were stacked together, forming constructs with evenly distributed cells and
endothelial cell-lined channels (190-192). Additionally, Khademhosseini and colleagues
have extensively engineered the self-assembly of cell-laden microgels (166, 193-197).
Other modular approaches have been recently reviewed (198).
Modularity is desirable because different microparticles may perform different
functions in the scaffold. We have recently developed scalable, aqueous methods for the
fabrication of stable microspheres from eight arm PEG-amine (PEG8-Am) and PEG8vinylsulfone (PEG8-VS), as well as hydrolytically degradable microspheres from PEG8Am and PEG8-acrylate (199, 200). The microspheres were modified with arginineglycine-aspartic acid (RGD) peptide to enable cell adhesion (201). Microspheres had
unreacted VS groups and aggregated by reaction with free amines in serum proteins,
enabling assembly of microsphere-based scaffolds. By including both degradable and
non-degradable microspheres, scaffolds with porosities on multiple length scales were
fabricated around HepG2 liver cells. Some microspheres released sphingosine-1phosphate (S1P), which promoted endothelial cell migration into the pores of the scaffold
(200). We have also utilized microsphere density differences to incorporate growth
factor gradients into microsphere-based scaffolds (202).
We continued to engineer these scaffolds with the goal of developing functional,
implantable cardiac tissues. Crosslinking of microspheres via serum proteins is
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undesirable because it may cause an antigenic response. Furthermore, the mechanical
strength of scaffolds crosslinked by the previous method was limited. We hypothesized
that by performing microsphere crosslinking in a cytocompatible dextran solution, phase
separation between dextran in solution and PEG in the microspheres would result in
microsphere aggregation and more rapid reaction kinetics. This may enhance the
strength of the scaffolds and eliminate the need for serum proteins to crosslink the
microspheres together. PEG/dextran aqueous two-phase systems have been widely used
for cellular and molecular partitioning (203-207). Two-phase dextran/PEG solutions
have also been used to produce microspheres and alter the porosity of hydrogels (208212). Dextran solutions were therefore seen as an attractive choice for enhancing the
crosslinking of PEG microspheres in the presence of HL-1 cells (a cardiomyocyte cell
line), allowing in vitro expansion and long-term culture in the resulting porous 3D
scaffolds.

2.3 Materials and Methods
2.3.1 Synthesis of PEG derivatives
Eight arm PEG-vinyl sulfone (PEG8-VS) and eight arm PEG-amine (PEG8-Am)
were synthesized from eight arm PEG (Creative PEGworks) as previously described (213,
214). Stock solutions of polymers (20%) in phosphate buffered saline (PBS) were
sterilized by filtration (0.22 µm, Millipore). For fluorescent labeling, 20% PEG8-Am and
Dylight-633 NHS ester (Pierce) were reacted overnight at 25ºC at a 100:1 molar ratio of
PEG:dye.
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2.3.2 Microsphere formation
PEG8-VS and PEG8-Am stock solutions (20%) were mixed at a 2:1 volume ratio
and pre-reacted at 37ºC for 70% of the time needed to reach bulk gelation (5.25 h). The
pre-reacted solutions were aliquoted and stored at -80ºC. RGD cell-adhesion peptide (1
mM, sequence: GCGYGRGDSPG, Genscript) was added to the pre-reacted solution and
reacted at 37ºC for 30 min. For microsphere formation, PBS and 1.5 M Na2SO4 were
pre-warmed to 37º C. Pre-reacted solution (50 µL, room temperature) was then diluted
with pre-warmed solutions in an Eppendorf tube to a final concentration of 2% PEG and
0.6 M Na2SO4 (500 µL total). Phase separation occurred upon addition of Na2SO4. The
mixture was triturated once and quickly transferred to a 37ºC heating block. Reaction
above the cloud point proceeded for 45 min. Microsphere suspensions were then diluted
3:1 in PBS, centrifuged at 14,100 g for 2 min, and the supernatant was replaced with an
equivalent volume of PBS. This was repeated 2x to ensure all Na2SO4 was removed.
After the final centrifugation, the pellet was resuspended in 500 µL of PBS. The postswelling microsphere volume was determined by measuring the total volume of solution
after the addition of 500 µL of PBS. Microspheres were stored in PBS at 4 ºC and were
stable for at least 6 months.

2.3.3 Microsphere sizing, swelling and aggregation
For microsphere sizing, aggregation was minimized by incubating microspheres
in a 350 µM cysteine solution for 2 hr at 25ºC to cap free VS groups. Fluorescent
microspheres (5 µL) were suspended in 45 µL of PBS, then 350 µL of dextran in PBS
was added just prior to imaging to attain the desired dextran concentration. Suspensions
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were vortexed for 30 sec, then samples (10 µL) were imaged on a glass slide by confocal
microscopy. Microsphere diameters (n > 40 microspheres per group) were measured
using ImageJ software (National Institutes of Health) and volumes were calculated
accordingly. Reported values are averages from 3 separately made microsphere batches,
with error bars representing the 95% confidence interval.
To investigate dextran-induced aggregation, fluorescent microspheres were
resuspended at a 1:1 volume ratio with 2%(v/v) fetal bovine serum (FBS, Sigma-Aldrich)
or 20% or 40% dextran (Mr = 100,000, Sigma Aldrich) in PBS. Suspensions were
vortexed and incubated at room temperature for 15 min. Aggregation of microspheres
was assessed by fluorescence microscopy. Dextran concentrations are reported
as %(w/v).

2.3.4 HL-1 culture
HL-1 cells, a gift from Dr. William Claycomb, are a continuously proliferating
cardiomyocyte cell line derived from mouse atrial tumors (215, 216). Cells were
maintained according to the protocol supplied by the Claycomb lab (217). Briefly,
Claycomb Medium (Sigma) was supplemented with 10% FBS, 100 µg/mL
penicillin/streptomycin, 0.1 mM norepinephrine, and 2 mM L-glutamine.
Supplementation with norepinephrine is key to maintenance of the contracting cardiac
phenotype (215-217). Cells from passages 50-70 were seeded at a density of 105/cm2
onto gelatin/fibronectin coated plates, supplied daily with 1 mL medium per 5 cm2
culture area, and split 1:3 every 3.5 days. HL-1 monolayers were contractile by day 3
after passage.
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2.3.5 Scaffold formation
Scaffolds crosslinked via serum proteins were fabricated as previously described
(200). For scaffolds crosslinked without serum proteins, dextran (20% unless otherwise
noted) was dissolved in serum-free DMEM if cells were present or PBS otherwise.
Scaffolds were made using 50 µL of RGD-containing microspheres. HL-1 cells were
removed from flasks by trypsin dissociation, then rotated in 1.65 mL serum-free DMEM
in an Eppendorf tube with the RGD-containing microspheres (107 HL-1s/mL
microspheres) for 1 h at 37ºC to promote cell adhesion (the “adhesion step”). The cells
and microspheres were centrifuged at 500 g for 3 min and the supernatant was removed.
Dextran-containing serum-free DMEM was added at a 1:1 volume ratio with the
microspheres to resuspend the pellet. The suspension was centrifuged at 500 g for 3 min,
then transferred to 37 ºC/5% CO2 for 1 h. Scaffolds were transferred to 6-well plates (BD
Falcon) containing either Claycomb medium if cells were present, or PBS otherwise.
Claycomb medium (4 mL) was replaced daily. Post-swelling dimensions were
approximately 8 mm in diameter and 1 mm in thickness.

2.3.6 Microstructural and mechanical analyses of scaffolds
Confocal microscopy was used to enable measurement of scaffold porosity in the
hydrated state. At least 8 confocal images per scaffold (n=3) were taken at randomly
selected depths and analyzed in Matlab (MathWorks Inc.) to calculate percent porosity
(area without microspheres/total area). Scaffolds for oscillatory shear rheometry (RFS3,
Rheometric Scientific) were made using 100 µL microspheres and were crosslinked in
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Eppendorf tubes (PDMS was used to fill the conical portion of the tubes such that
crosslinking occurred in the top of the tube). PBS-hydrated scaffolds (1 mm thick) were
die cut to 8 mm and characterized using 8 mm parallel plates, with a normal force of 40
mN to prevent slipping. An amplitude sweep (G′ as a function of strain) was performed
to confirm that measurements were in the linear viscoelastic regime. Frequency sweeps
(1-100 radians/second) were then performed at 5% strain.

2.3.7 Characterization of HL-1 response to scaffolds crosslinked in 20%
dextran
For cell-viability analysis, scaffolds were incubated in serum-free DMEM
containing calcein AM (2 µM) and ethidium bromide (4 µM) (Invitrogen) for 30 min.
Ten images per scaffold (n=3) were taken at randomly selected depths and analyzed in
Matlab to calculate percent viability. For measurement of scaffold cell densities, scaffold
volume was measured prior to storage at -80 ºC. At the time of the assay, scaffolds were
thawed, mechanically dissociated by pipetting, and suspended to a final volume of 1 mL
in dye/cell lysis buffer from a cell quantification kit (CyQUANT®, Invitrogen,
excitation/emission: 480/520 nm). Suspensions were vortexed for 2 min, and 5 µL
samples were diluted in an additional 195 µL of dye/lysis buffer on a 96-well plate.
Spectrofluorometric measurements were compared to a standard curve of known HL-1
densities.
To ensure that cells were well distributed throughout the depth of the scaffold, a
thicker (~1.65 mm), fluorescently labeled scaffold was fixed (24 hr after scaffold
crosslinking) in 3.7% formaldehyde for 45 min at room temperature then treated with
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30% sucrose solution for 3.5 h at room temperature for cryoprotection. Scaffolds were
frozen in OCT (Tissue-Tek®, Sakura) at -80º C for 30 min then cryostat sectioned with
careful attention to depth of sectioning. Nine evenly spaced serial sections (16 µm
thickness) were treated with a nuclear stain (Hoescht 33258, Molecular Probes, 1:1000 in
PBS) for 15 min at room temperature prior to imaging by fluorescence microscopy. The
first 3 sections were designated as the top region of the scaffold, the middle three as the
center, etc., with each region being ~550 µm thick. Fifteen cell counts were made per
region, averaged and divided by the average area of microspheres for that region.
For immunohistochemistry (IHC), non-fluorescent scaffolds were prepared for
cryostat sectioning as described above. After sectioning, slides were
blocked/permeabilized in 10% normal donkey serum/0.1% Triton X-100 in PBS.
Primary antibodies were goat anti-connexin 43 (cx43, 1:100 dilution, Santa Cruz
Biotechnologies, SC6560) and rabbit anti α-actinin (1:500, Sigma Aldrich, A2543).
Alexa Fluor 488-labeled donkey anti-goat (1:1000, Invitrogen, A11055) and Cy5-labeled
donkey anti-rabbit (1:100, Chemicon, AP1825) secondary antibodies were used to
visualize the staining. Coverslips were added with Vectashield® mounting medium
containing DAPI (Vector Labs) for nuclear detection.

2.3.8 Microscopy
For scanning confocal microscopy (Eclipse C1/80i, Nikon), a hydrated scaffold
was placed on a glass slide and covered with a circular glass coverslip (150 µM thick).
PBS was pipetted under the coverslip to prevent dehydration. For scanning electron
microscopy (SEM, NanoSEM 2300, FEI Nova), hydrated scaffolds were fixed in 3.7%
formaldehyde for 30 min at room temperature, suspended in diH2O, frozen in liquid
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nitrogen, and freeze-dried overnight. Scaffolds were gold-coated (Cressington 108) and
imaged at 15 kV. Images of fluorescent microspheres and immunohistochemistry (IHC)
were acquired by fluorescence microscopy (IX70, Olympus) using a Magnafire camera
(Optronics).

2.3.9 Detection of HL-1 electrical activity
Calcium sensitive Fluo-4 AM (10 mM in DMSO, excitation/emission: 494/516
nm, Invitrogen) was mixed (1:1 volume ratio) with 20% (w/v) Pluronic® F-127
(Invitrogen), diluted to 10 µM in DMEM, and applied to scaffolds for 30 min at 37ºC/5%
CO2. Scaffolds were washed 3x in PBS and incubated 15 min in DMEM + 0.1 mM
norepinephrine to allow for complete de-esterification of the Fluo-4. Scaffolds were
rinsed once in Tyrode’s solution (1.33 mM CaCl2, 1 mM MgCl2, 5.4 mM KCl, 135 mM
NaCl, 0.33 mM NaH2PO4) containing 0.1 mM norepinephrine, 5 mM glucose, and 5 mM
HEPES, and this solution was used to keep scaffolds hydrated during imaging.
Norepinephrine is required in the culture media to maintain the beating phenotype over
long culture periods, and was similarly added to the Tyrode’s solution (215-217).
Electrical stimuli were delivered to tissue constructs via a bipolar electrode made of two
silver microwires (8 mil, A-M systems Inc.) inserted under the glass cover slips and into
the Tyrode’s solution surrounding the scaffolds. Sequences of images (sampling rate = 1
- 2 Hz) were acquired by confocal microscopy at a depth of 100 µm into the scaffold
while monophasic electrical impulses were applied to the scaffolds (amp = 10 V, duration
= 200 msec, frequency= 1 Hz, burst width = 10 sec.) using an isolated pulse stimulator
(Model 2100, A-M systems Inc.). Resulting images were analyzed using Matlab
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software for temporal patterns of fluorescence. Average fluorescence intensity was
calculated over time for 8x8 pixel regions within the field of view, which were
normalized to location-specific background intensity values to remove biases associated
with the variability in cell density across the scaffold.

2.3.10 Statistics
Comparisons between 2 means were by Student’s T-Test with p < 0.05 considered
significant. Three or more means were compared by ANOVA with post hoc Scheffe test
in Matlab with p < 0.05 considered significant. Data are mean ± standard deviation or
95% confidence interval, as specified in the text.

2.4 Results
2.4.1 Effect of dextran on PEG microsphere swelling and aggregation
Individual microsphere diameters were used to calculate the average individual
microsphere volume across a range of dextran concentrations. These were normalized to
average volume of microspheres in PBS (diameter: 20.1 ± 5.3 µm, volume: 2109.8 ±
1066.1 µm3). Microsphere volume did not significantly change in the presence of 2%
serum (1.0 with a 95% CI of 0.8-1.3 as normalized to PBS alone), but decreased upon the
addition of dextran, becoming more compact as dextran concentration increases (Fig. 2.1
A). The wide variation in volume between microsphere batches at 5% dextran was
because this was close to the critical concentration for phase separation. PEG
concentration increases upon deswelling, enabling increased crosslinking between free
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VS and Am groups. Phase separation also causes microspheres in dextran solutions to
aggregate, with increased packing at higher dextran concentrations (Fig. 2.1 B; note that
the dextran concentration prior to dilution 1:1 (v/v) with PEG microspheres is reported).
This compaction should increase the local concentration of PEG for microsphere-to-

Figure 2.1 Phase separation in dextran increases localized PEG concentration through microsphere
deswelling and aggregation. (A) The effect of dextran concentration on microsphere size was studied.
Fluorescent microspheres were suspended in dextran solutions of varying concentrations. Care was taken to
diminish microsphere aggregation prior to confocal imaging. Microsphere volumes () were determined by
image analysis (n=3 microsphere batches, >40 microspheres per batch) and plotted alongside corresponding
microsphere PEG concentrations () (both normalized to PBS alone =1). Microspheres showed a decreasing
size trend with increasing dexran concentrations. Error bars correspond to the 95% confidence intervals at
each point. (B) Pelleted fluorescent microspheres were resuspended at a 1:1 volume ratio in 2% fetal bovine
serum, 20% dextran or 40% dextran, vortexed for 1 minute, allowed to aggregate at 25°C for 15 min, and
imaged by fluorescence microscopy. Magnified insets highlight the packing of multiple microspheres to form
large aggregates at higher dextran concentrations.
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microsphere crosslinking.

2.4.2 Fabrication and swelling of scaffolds crosslinked in 20% dextran
Due to the higher density of the dextran solutions, centrifugation resulted in
microspheres rising to the top of the solution (Fig. 2.2 A). Scaffolds made by our
previous method (via serum proteins) required overnight immobilization for crosslinking
into scaffolds that were strong enough to support their weight in solution, but could not
be removed from the centrifugation container. Scaffolds fabricated in 20% dextran could

Figure 2.2 Microsphere scaffold formation and swelling. (A) Microspheres were suspended in medium
containing either 2% serum or 20% dextran, centrifuged, then crosslinked to form scaffolds. Phase
separation in dextran allowed microsphere crosslinking in the absence of serum proteins. Scaffolds
formed in dextran were much stronger and could be transferred to cell culture plates and cell-specific
medium after only 1 h at 37°C. Scaffolds crosslinked in 2% serum had to be kept in the same tubes in
which they were formed to avoid breakage. (B) To demonstrate microstructural changes caused by
swelling upon dextran removal (after crosslinking step), a scaffold crosslinked in 40% dextran was
imaged by confocal microscopy before and after buffer exchange into PBS.
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be removed from their centrifugation containers after just one hour. The microsphere
swelling data (Fig. 2.1 A) helps to explain this phenomenon. Being a second order
reaction, the 4-fold increase in PEG concentration in 20% dextran should increase the
rate of the crosslinking reaction 42 =16 fold. Sixteen hours approximates the previously
used overnight crosslinking step. Scaffolds that were crosslinked in dextran
demonstrated substantial re-swelling upon transfer to physiological buffer (Fig. 2.2 B).

2.4.3 Scaffold microstructure and mechanical properties
We noted that scaffolds crosslinked in dextran better withstood routine handling,

Figure 2.3 Scaffolds crosslinked in the presence of 20% dextran are stiffer. Storage moduli (G′) of
microsphere scaffolds crosslinked in either 20% dextran (n=3) or 2% serum (n=2) in PBS, 1 d after
scaffold formation. Error bars = std. dev. *p < 0.05 for all frequencies
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possibly due to denser microsphere-to-microsphere crosslinking afforded by the increases
in local PEG concentration. Parallel plate rheometry was used to quantify differences in
stiffness. The storage moduli of scaffolds crosslinked in 20% dextran was approximately
3 times higher than the previously published scaffolds crosslinked in 2% serum (Fig. 2.3)
(200). However, the nonlinearity of the storage modulus curve is unusual, and further
characterization is needed to confirm the value.
Interestingly, confocal microscopy demonstrated larger pores in scaffolds
crosslinked in dextran compared to scaffolds formed by centrifugation in 2% serum
without dextran (Fig. 2.4). Scaffolds crosslinked in 2% serum without dextran were not

Figure 2.4 Scaffolds crosslinked in the presence of 20% dextran have increased porosity. Hydrated
scaffolds containing fluorescently labeled PEG8-Am were imaged by scanning confocal microscopy (top
row). Fixed and dehydrated scaffolds were also analyzed by scanning electron microscopy (bottom
row). Microsphere-based scaffolds were compared to bulk PEG hydrogels made from the same
precursors by Michael-type reaction (2:1 PEG8-VS:PEG 8-Am). Scaffolds formed in dextran were
porous without the addition of porogens. Scaffolds formed in 2% serum appeared to be porous, but
these are actually large fractures, and the microspheres are otherwise tightly packed.
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highly porous, thus requiring porogens to enhance porosity (200). These scaffolds also
fractured easily, making it impossible to quantify their porosity by image analysis.
Scaffolds crosslinked in the presence of 20% dextran were porous (42.9 ± 1.2% porosity,
n=3) even without addition of a porogen. We suspected that this was due to precrosslinking of the microspheres upon addition of dextran, perhaps around spherical
dextran-rich droplets, leading to inefficient packing upon centrifugation. SEM images of
these scaffolds are in general agreement with the scanning confocal images. However, it
is clear that SEM drying artifacts make interpretation of scaffold porosity much more
tenuous, and that scanning confocal microscopy is clearly superior for characterizing
porosity (218).

Figure 2.5 HL-1 cells retain high cell viability in scaffolds assembled in the presence of 20%
dextran. (A) Scaffolds (blue) were formed from microspheres with and without RGD peptide. HL-1
cells were mixed with the microspheres and rotated for 1 h at 37°C to promote attachment of the
cells to the microspheres prior to scaffold formation in 20% dextran. One day after scaffold
formation, HL-1 cells were labeled with calcein AM (green) and imaged by scanning confocal
microscopy. Cells were more spread in scaffolds with RGD peptide. (B) Live/dead assay of HL-1
cells in a scaffold 1 d after cross-linking, as imaged by confocal microscopy. Cell viability was
81.2 ± 4.7% (n = 3).
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2.4.4 HL-1 incorporation, viability, and proliferation in microsphere
scaffolds crosslinked in the presence of 20% dextran
Scaffold fabrication in dextran solutions was also possible in the presence of
living cells, giving well distributed cell density throughout the scaffold’s thickness
(Supplementary Fig. S2.1). To enable cell adhesion to the microspheres, RGD peptides
were reacted with PEG8-VS during the pre-reaction stage, as previously described (200).
Cells in RGD-containing scaffolds had a more spread morphology, as expected (Fig. 2.5
A). Cell viability 24 h after scaffold fabrication was 81.2 ± 4.7% (Fig. 2.5 B, n=3). The
cell density with 1 mM RGD-containing microspheres, measured 2 h after transfer of the

Figure 2.6 HL-1 cell proliferation in scaffolds. (A) HL-1 cell density immediately following scaffold
formation (day 0) and after 6 and 13 days. Cell density increased nine-fold by day 13. *p<0.05
versus day 0 and day 6. (B) HL-1cells labeled at day 0 with Cell-Tracker dye (green) then
incorporated into scaffolds (blue) to follow the increase in cell density over time. Scanning confocal
images are from the interior of each scaffold.
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scaffold to cell-specific medium, was 2.2 ± 0.3 million cells/mL scaffold (n=3), and only
slightly higher by day 6 (Fig. 2.6 A). However, by day 13, HL-1 cells had proliferated to
a density of 18.3 ± 1.0 ×106 cells/mL scaffold (Fig. 2.6 A, n=3), and much of the porous
space in the center of the scaffold was filled with HL-1 cells (Fig. 2.6 B). Proliferation of
cells resulted in the formation of large cell clusters in the pores of the scaffold that
changed the macroscopic appearance of the scaffold (Supplementary Fig. S2.2).
The experimental design of the proliferation assay originally contained control
scaffolds that were crosslinked via serum proteins. However, they broke if removed from
their centrifugation containers. In our previous study (200), scaffolds were maintained in
the centrifugation containers and the latest time point was 108 hr (meaning 2-3 media
changes). It is difficult to maintain serum protein-based scaffolds in centrifugation

Figure 2.7 HL-1 cells express cardiac functional markers after long term culture in microsphere-based
scaffolds crosslinked in 20% dextran. Immunohistochemical staining for connexin 43 (green),
sarcomeric α-actinin (red), and DAPI (blue) at: (A-C) day 13 and (D-F) day 24 after scaffold
formation. (A and D) Low magnification view of both sarcomeric α-actinin and connexin 43. (B and E)
Magnified staining for connexin 43/DAPI alone and (C and F) sarcomeric α-actinin/DAPI alone.
Connexin 43 staining was punctuated suggesting substantial cell-cell contacts, while sarcomeric αactinin expression indicated that cells had retained the cardiomyocyte phenotype. Section slices were
10 µm thick for all images. Images were acquired by fluorescence microscopy.
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containers much longer than that because frequent media changes cause scaffold
breakage.

2.4.5 HL-1 expression of cardiac functional markers in microsphere
scaffolds crosslinked in the presence of 20% dextran
When cultured on two-dimensional substrates, HL-1 cells are known to express
both connexin 43 and sarcomeric α-actinin, which are key proteins in excitation and
contraction of myocytes, respectively (215, 216). Punctuated expression of the gap
junction connexin 43 indicates connexon/gap junction assembly and suggests
intercellular electrical connectivity. These markers were probed by
immunohistochemistry at days 13 (Fig. 2.7 A-C) and 24 (Fig. 2.7 D-F) after crosslinking.
Extensive proliferation (Fig. 2.7 E-F) and cell clustering (Fig. 2.7 D) was further
confirmed by nuclear staining at day 24. Both connexin 43 (Fig. 2.7 B and 2.7 E) and
sarcomeric α-actinin (Fig. 2.7 C and 2.7 F) were expressed at day 13 and continued to be
expressed through day 24 (Fig. 2.7). The continued expression of these proteins
suggested that the cells retained their cardiomyocyte phenotype during culture in the
microsphere scaffold and were capable of electrical communication via gap junctions.

2.4.6 Detection of HL-1 electrical excitation in microsphere scaffolds
crosslinked in the presence of 20% dextran
As a final test of maintenance of cardiac phenotype, we looked at HL-1 excitation
after over 5 weeks in culture. Activation of HL-1 cells in day 38 scaffolds was detected
by confocal microscopy of Fluo-4 stained cells (Fig. 2.8). Fluorescence intensity traces
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were collected for multiple pixels in different regions of interest (ROI). Pixel traces
shown in a single ROI graph are spaced by a distance of at least 16 µm, such that some of
the traces were likely from adjacent cells. Spontaneous excitation was observed
throughout the scaffolds (Fig. 2.8 A), with pixels from various areas of a single ROI
peaking simultaneously. This suggests some degree of electrical connectivity between
cells of a single cluster. The duration of the spontaneous transients varied between ROIs,
possibly due to variation in the activity of Ca2+-ATPase on the surface of the
sarcoplasmic reticulum. In paced scaffolds, cells in various ROIs were excited at the
same frequency (0.5 Hz) for the 10 s duration of the stimulus (Fig. 2.8 B). Surprisingly
the excitation frequency of these clusters was only half the stimulation frequency (i.e. a
2:1 block), suggesting that the cells have a long refractory period (normal murine
refractory periods are on the range of 50 ms (219)).
Contraction of cell clusters was not visualized at the microscopic level, but the
use of an excitation-contraction uncoupler (e.g. blebbistatin) would be necessary to
absolutely verify that transients were not influenced by contraction-induced motion.
Although the traces do not appear to represent pure action potential, the presence of
calcium transients and/or motion indicate that the cells are still electrically active after 5
weeks in the 3D scaffolds. This suggests a promising outlook for future work
investigating HL-1s or other types of cardiomyocytes. Future studies will focus on
optimization of materials to support a contractile phenotype.
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Figure 2.8 HL-1 cells retain electrical activity after 38 days of culture within microsphere-based scaffolds
crosslinked in 20% dextran. Day 38 scaffolds containing HL-1 cells were incubated with calcium-sensitive
Fluo-4 AM to monitor changes in intracellular calcium concentrations. Activity was imaged by scanning
confocal microscopy at a depth of 100 µm into the scaffolds. (A) Spontaneous transients were seen in
various regions of interest (ROI) throughout the scaffold. (B) Transients from various ROI in response to
stimulation by monophasic electrical impulses (amplitude = 10 V, duration = 200 msec, frequency= 1
Hz, burst width = 10 sec). Traces of transients from different ROI or random pixels are shown. The
multiple traces from within each ROI were from pixels spaced at least 16 microns apart.
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2.5 Discussion
Phase separations have been utilized to produce porous hydrogel materials for at
least five decades (220-222). Crosslinking of a polymer above its LCST results in the
formation of sponge-like morphologies that sometimes appear to be aggregates of
microspheres (218, 223-225). The current method differs from traditional phase
separation methods because scaffold formation is divided into a microsphere formation
step and a microsphere assembly step. Like our previously reported methods (199, 200),
the microsphere formation step is performed in sodium sulfate solutions rather than
dextran because the microsphere yield is much higher. The scaffold formation step is
then performed in cytocompatible dextran solution, which provides a stiffness increase
that enables more extensive biological characterization than was possible using the serum
protein-based protocol. The two-step method allows the fabrication of large quantities of
high quality microspheres that may be stored for longer than six months prior to scaffold
formation. It is our experience that the complexity of processing materials in the phaseseparated state is mostly captured in the first step. Thus, if the first step yields high
quality microspheres, the same microsphere batch may be used over the course of many
experiments.
Materials used for cardiac tissue engineering are typically: 1) macroporous
scaffolds formed apart from cells, or, 2) non-macroporous hydrogels crosslinked around
cells. As an example of pre-formed scaffolds, Langer and colleagues produced highly
porous poly(glycerol sebacate) materials that had mechanical properties similar to
myocardium (226). The scaffolds were engineered with intricate, biomimetic pore
structures that promoted the alignment of cardiomyocytes (227). As an example of a
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non-macroporous hydrogel, collagen gels have been extensively characterized by
Eschenhagen, Zimmermann, Elson and colleagues (131, 179, 228-232). Primary heart
cells were added to collagen solutions prior to gelation. Cardiac fibroblasts contracted
the gels, which resulted in highly aligned, electrically active tissues (131, 179, 228-232).
While the lack of porosity may place size limitations on the tissues, researchers have
circumvented this problem by fusing multiple small collagen gels to create larger cardiac
patches (131, 231, 232).
Materials for cardiac tissue engineering must be especially resistant to the
formation of a fibrous capsule, which may result in electrical isolation of the transplanted
tissue. Because of its low protein adsorption properties, PEG is an excellent candidate
for these types of applications (142, 153, 233). The PEG-based scaffolds described here
are macroporous when assembled in the presence of living cells. Similar to traditional
macroporous scaffolds, the cells have space within the pores to migrate and proliferate.
Similar to a collagen gel, the cells are evenly distributed regardless of scaffold thickness
from the time of scaffold formation. The storage modulus is also higher than reported
values for collagen gels (10-100 Pa) (234-237).
Collagen gels are typically remodeled by cardiac fibroblasts that are present in the
primary heart cell harvests. Unfortunately, proliferating fibroblasts may quickly overtake
the cardiomyocytes, limiting the window of study to a few days and making it difficult to
analyze cardiomyocyte-specific responses (231, 238). While patient-derived stem cells
may be the optimal cell source for cardiac tissue engineering, HL-1 cells are a useful
model for studying cell responses to biomaterials because they maintain many of the
characteristics of cardiomyocytes. HL-1 monolayer cultures have previously been used
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to probe cardiomyocyte responses to various drugs and other treatments (216, 239-241).
Several recent studies have used HL-1 cells to study cardiomyocyte responses to
biomaterials (242-245). For example, Stupp and colleagues demonstrated HL-1
alignment and electrical activity at day 10 in nanofibrous amphiphilic peptide gels (242),
but viability and retention of cardiac phenotype in longer-term cultures were not
investigated. Jongpaiboonkit et al. investigated viability over time for HL-1s
encapsulated in bulk PEG-diacrylate hydrogels, which have negligible porosity (245).
Viability in non-degrading bulk gels at day 1 was slightly higher than what was seen in
the PEG microsphere scaffolds (~90% versus ~81%, respectively). This slight viability
difference may be a product of the length of the adhesion step used to ensure HL-1
adhesion to microspheres during centrifugation. At two weeks, HL-1 viability in the bulk
PEG hydrogels was low unless RGD density and degradation rate were finely tuned (245).
In the current study, HL-1 cells expressed functional markers and had a nine-fold
increase in cell density at two weeks. While a long-term comparison between the
systems has not yet been performed, HL-1 cells in PEG microsphere-based scaffolds may
be at a long-term advantage due to increased porosity and nutrient diffusion.
However, the current scaffolds still need to be improved to be useful for cardiac
tissue engineering. While dense cardiomyocyte packing is important for conduction,
localized HL-1 proliferation caused clustering within the pores of the scaffold, and the
cells lacked the alignment and highly organized gap junctions (Figs. 2.6 and 2.7) typical
of natural myocardium. Furthermore, the frequency of spontaneous transients in the
scaffolds was lower than those reported for confluent HL-1 monolayers (246) and seen in
our own two-dimensional cultures, but similar to what is reported for non-confluent
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monolayer cultures (239). The lower frequency and lack of synchronization in
spontaneous transients probably indicates low electrical conduction between cell clusters
in the scaffold. Functionalizing some of the PEG microspheres with enzymatically
degradable sites may enhance porosity and help the cells to remodel their environment,
similar to what is seen in collagen gels (161, 229). Coupling enzymatic degradation with
mechanical (230) and/or electrical (247) stimulation may further improve cellular
alignment and electrical conduction.
Finally, replacing the HL-1 cells with an autologously derived cardiomyocyte
source will be necessary before the engineered tissue can be used in a clinical setting.
Recent studies have found that matrix stiffness (159, 164, 248) and topography (101, 107,
110) have profound influence on cell differentiation and maturation, so it is possible that
the mechanical differences observed in this study would affect cell phenotype. However,
the microstructural differences between PEG microsphere scaffolds and those described
by other groups limit our ability to hypothesize on the outcome of mechanical and
topographical changes. Our future research will likely include variation of microsphere
size and stiffness and its effects on stem cell differentiation and cardiomyocyte phenotype.

2.6 Conclusions
In this study, previously published modular scaffold fabrication methods were
improved, developing stronger, more porous PEG scaffolds by crosslinking microspheres
in the phase separated state. Scaffolds were assembled around HL-1 cardiomyocytes, and
cells were cultured in the scaffolds for over a month. The HL-1 cells proliferated,
expressed cardiomyocyte markers, and retained electrical activity.
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2.8 Supplementary Figures

Supplementary Figure S2.1 HL-1 cells are well distributed throughout the thickness of a
microsphere scaffold crosslinked in 20% dextran. Cell nuclei (yellow) in sections from a day 1
scaffold were counted and the average number per mm2 of microspheres (blue) was calculated for
three scaffold regions (each representing 550 µm of scaffold thickness). (A) Images of sections used
for cell counts. (B) A bar graph presenting the average cell density in the top, center and bottom of
the scaffold. Error bars represent standard deviation between 3 sections in one scaffold region.
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Supplementary Figure S2.2 Macroscopically visible HL-1 clusters are present after 10 days of culture
in a microsphere scaffold crosslinked in 20% dextran. A phase contrast image of an HL-1 loaded
scaffold, 10 d after scaffold formation, compared to a scaffold without cells. White arrows indicate
visible clusters of HL-1 cells.
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CHAPTER 3*
Direct reprogramming of mouse fibroblasts to
cardiomyocyte-like cells using Yamanaka factors
on engineered poly(ethylene glycol) hydrogels
3.1 Abstract
Direct reprogramming strategies enable rapid conversion of somatic cells to
cardiomyocytes or cardiomyocyte-like cells without going through the pluripotent state.
A protocol recently described by Efe et al. (Nature Cell Biology, 2011, 13:215) couples
Yamanaka factor induction with pluripotency inhibition followed by BMP4 treatment to
achieve rapid reprogramming of mouse fibroblasts to beating cardiomyocyte-like cells.
The original study was performed using Matrigel-coated tissue culture polystyrene
(TCPS), a stiff material that also non-specifically adsorbs serum proteins. Protein
adsorption-resistant poly(ethylene glycol) (PEG) materials can be covalently modified to
present precise concentrations of adhesion proteins or peptides without the unintended
effects of non-specifically adsorbed proteins. Here, we first reproduced the Efe et al.
protocol to reprogram adult mouse tail tip mouse fibroblasts (TTF) and mouse embryonic
fibroblasts (MEF) to cardiomyocyte-like cells that demonstrated striated sarcomeric αactinin staining, spontaneous calcium transients, and visible beating on Matrigel-coated
TCPS. We then designed poly(ethylene glycol) culture substrates to promote MEF
*

Chapter 3 is adapted from a manuscript accepted for publication in Biomaterials May
23rd, 2013. DOI: 10.1016/j.biomaterials.2013.05.050
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adhesion via laminin and RGD-binding integrins. PEG hydrogels improved proliferation
and reprogramming efficiency (evidenced by beating patch number and area, gene
expression, and flow cytometry), yielding almost twice the number of sarcomeric αactinin positive cardiomyocyte-like cells as the originally described substrate. These
results illustrate that cellular reprogramming may be enhanced using custom-engineered
materials.

3.2 Introduction
Heart failure is one of the most common health problems in the United States. It
will eventually affect ~20% of all 40-year-old Americans (11). Innovative solutions are
necessary to reduce the costs of heart failure, which currently stand at ~$39.2 billion per
year (11). Cell-based therapies, or introduction of healthy cells into cardiac scar tissue,
have modestly improved various measures of cardiac function (60, 249, 250). The best
donor cell source is still under debate, with much room for optimization across cell types
(58). Current cardiomyocyte derivation strategies include differentiation from embryonic
stem cells (ESCs), induced pluripotent stem cells (iPSCs), resident cardiac progenitor or
stem cells, or direct reprogramming, which bypasses the pluripotent state. ESC and iPSC
(collectively, PSC)-derived cardiomyocytes are expandable, and iPSC-derived
cardiomyocytes could be autologously sourced. However, their populations must be
carefully purified to avoid risks of teratoma formation, and chromosomal defects arising
over long periods in culture add to tumorogenic risks (46). Currently, iPSC derivation is
relatively inefficient (0.01-1.4%) (78). The full derivation, expansion, and purification of
pluripotent stem cell derived cardiomyocytes can take several months (36, 79).
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Several direct reprogramming strategies (75, 76, 82, 84) have reported bypassing
the pluripotent state, enabling autologous derivation of cardiomyocyte-like cells in a
fraction of the time needed for iPS cell production. This has been achieved by inducing
transcription factors important for cardiac development (for example; Tbx5, Mef2c,
Gata4, Myocd and/or Hand2) (75-77) or using microRNAs (82) to control signaling
pathways. In addition to implanting cells reprogrammed in vitro, similar techniques have
been used to reprogram scar tissue to cardiomyocytes in vivo (77, 80-82). The direct
reprogramming protocol described by Ding and colleagues (Efe et al. (84)) combines a
carefully timed induction of Oct4, Sox2, Klf4, and c-Myc (OSKM), inhibition of the
JAK-STAT (Janus kinase-signal transducer and activator of transcription) pluripotency
pathway, serum withdrawal, and BMP-4 mediated cardiogenic induction, resulting in
beating patches of cells in as little as 11 days after OSKM induction (84). The rapid
derivation process is especially relevant in cases of myocardial infarction, as the
inflammatory response begins within 24 hours (86) and scar formation progresses quickly
from there (87).
Extracellular matrix (ECM) proteins in the cell microenvironment affect
pluripotent differentiation via integrin signaling, and are well known to direct
differentiation down varied pathways (100). However, the optimal surface density and
types of proteins are often determined by trial and error. Efe et al. found that Matrigel
(~60% laminin-1, ~30% collagen IV, ~8% entactin, ~2% other proteins according to
product literature) improved cardiac direct reprogramming over Geltrex, gelatin or
fibronectin coatings, but no mechanism was proposed (84). In contrast, Thomson and
colleagues revolutionized PSC culture by measuring ESC growth factor receptor
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expression and tailoring the media formulation accordingly (251, 252). Recently, Koche
et al. analyzed global gene expression of partially reprogrammed mouse embryonic
fibroblasts (MEFs, 3 days into OSKM induction), reporting upregulation of lamininbinding integrin subunits α6 (4.0-fold) and β4 (13.3-fold), downregulation of collagen IV
binding subunits α1 (4.3-fold), and little changes in expression of many RGD motifbinding integrin subunits (e.g. α5 and αV), with the exception of α8, downregulated 4fold (253). Based on these data, we hypothesized that laminin alone would promote the
direct reprogramming of MEFs to cardiomyocyte-like cells at least as well as Matrigel.
The use of laminin also avoids the batch-to-batch variation in protein content seen with
Matrigel (254, 255). We also hypothesized that the addition of RGD peptide would
enhance cell adhesion on engineered substrates due to the continued expression of αV
during the early reprogramming process.
In the original direct reprogramming protocol, Matrigel was adsorbed to tissue
culture polystyrene (TCPS) prior to cell seeding (84). However, adsorption may cause
unfolding of ECM proteins, resulting in altered cell signaling (256-259). Serum proteins
from the media also adsorb to TCPS, competing with the intended ECM proteins (260)
and activating unintended signaling pathways that may vary by batch of serum.
Poly(ethylene glycol) (PEG) is resistant to non-specific protein adsorption, but may be
covalently modified to present bioactive molecules at precise quantities and in their
native conformations (261, 262). For this study, we engineered PEG cellular
microenvironments that potentially provide better control over adhesion molecule
concentration, conformation, and stability than is possible with TCPS. We demonstrate
that these engineered hydrogel substrates lead to higher efficiency of direct
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reprogramming to cardiomyocyte-like cells than the protocol initially described by Efe et
al. (84)

3.3 Materials and Methods
3.3.1 Mouse protocols and fibroblast culture
All animal protocols were approved by Washington University Institutional
Animal Care Use Committee. A pair of mice homozygous for doxycycline-inducible
OSKM factors (Jackson Labs, stock number: 011011) was bred to start a colony for tail
tip (TTFs) and embryonic fibroblasts (MEFs) (263). To harvest tail-tip fibroblasts
(TTFs), adult tails were sterilized in 70% ethanol, skinned, and minced thoroughly.
Minced pieces were incubated in 3 mL of 0.05% trypsin-EDTA (Invitrogen) at 37ºC for
30 min then neutralized with 7 mL of fibroblast media (FB media: DMEM+10% fetal
bovine serum+1% ABAM). Tail pieces were collected by centrifugation, resuspended in
3 mL of FB media, and transferred by tweezers to gelatin coated wells (1 mL/well at 0.1
mg/mL, preincubated 1 h at room temperature) at a ratio of one tail per 2 wells of a 6 well
plate. Care was taken to dry the well surfaces by aspiration prior to placing the pieces,
and to evenly space the pieces in the well. After allowing 4 h for tails to adhere at 37ºC,
0.2 mL of FB media was added per well. The next day, 3 mL/well of FB media were
added. Once TTFs became confluent, they were trypsinized, strained through a 70 µm
cell strainer, and replated (2 wells/T75 flask). Once confluent, the flask was trypsinized
and frozen at -80 (1 cryovial per initial mouse tail).
For preparing mouse embryonic fibroblasts (MEFs), day 13.5 embryos were
harvested and the visceral organs removed to minimize the presence of cardiac precursor
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cells. Embryos were minced, incubated at 37ºC for 30 min in 7 mL of 0.05% trypsinEDTA and then triturated using a 10 mL pipet. Trypsin was neutralized with 23 mL of
FB media, divided into T75 flasks (2-3 embryos/flask), and cultured in 15 mL of FB
media. Once confluent, cells were passaged 1:3 and the passage 2 cells were trypsinized
and frozen at -80ºC (3 cryovials/confluent flask).

3.3.2 PEG hydrogel fabrication and functionalization of culture surfaces
All experiments were performed using 24-well plates. Thirty minutes prior to gel
fabrication, wells were treated with a plasma cleaner (Harrick Plasma) set to medium
(350 mTorr for 5 min) to reduce meniscus formation in the wells during gel formation.
Plates were then UV-sterilized for 30 min and gel precursor solutions were added
immediately. PEG derivatives were synthesized as previously described (213, 214, 264).
For gel fabrication, PEG8-Vs and PEG8-Am solutions (both 20% w/v in PBS, pH 7.4)
were sterile-filtered (0.22 µm filter) and diluted in 0.03 M NaOH in PBS (pH 8.75,
NaOH enhanced reaction kinetics and further reduced meniscus formation) for a final
PEG concentration of 12.43% (w/v). The precursor mix was aliquoted at 200 µL/well
and allowed to crosslink in a humidified incubator (37ºC) for 1-2 days.
Protein and peptide surface concentrations are reported as 1x or 5x. When
referring to Matrigel or laminin, 1x is the approximate protein concentration of Matrigel
used in Efe et al. The concentration used here may be slightly different than Efe et al. as
they reported the Matrigel dilution factor (1:40) instead of the coating concentration (84),
and so their surface concentration will vary by Matrigel batch (265). Here, we
standardized the 1x coating protein concentration at 11.4 µg/cm2 (the 1:40 dilution of our
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first Matrigel stock when used at 200 µL/well). The 1x concentration of laminin was also
set to 11.4 µg/cm2. When referring to the RGD peptide, 1x is the approximate surface
density of RGD on the PEG microspheres previously tested with HL-1 cardiomyocytes
(266).
For functionalization with Matrigel (BD Biosciences, 356234) or laminin-1
(Sigma, L2020), protein stocks were first diluted to 108.3 (1x) or 541.5 µg/mL (5x) in
PBS. If RGD peptide (GCGYGRGDSPG, Genscript) was included, it was diluted in the
same tube as the protein at 3.36 (1x) or 16.82 (5x) mg/mL. Each well received 200 µL of
protein/peptide solution. For TCPS conditions, (non-plasma treated) 24-well plates were
incubated at room temperature for 1 h to permit protein adsorption (according to Matrigel
product literature). The pre-formed PEG hydrogels were incubated with the
protein/peptide mixtures overnight at 37ºC to permit the slower, covalent Michael-type
reaction to occur. Fibroblast seeding occurred the next day.

3.3.3 Cell culture and reprogramming
All reagents were purchased from Invitrogen unless otherwise noted. Passage 3
fibroblasts were seeded at day -1 (minus one) onto the functionalized 24-well plates at
3,600 MEFs or 9,700 TTFs/cm2 and incubated overnight in FB media to ensure complete
adhesion. Reprogramming commenced the following day (day 0), and media was
changed every 24-48 hours. Media formulations and reprogramming timelines were
adapted from Efe et al. (84). Reprogramming timeline #4 (Fig. 3.1 a) was the most
efficient at producing beating in initial testing with MEF, and was used in all experiments
thereafter. From days 0-5, cells received knockout DMEM (KO DMEM, 10829018) + 2
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µg/mL fresh doxycycline (Sigma, D9891) + 0.5 µM JAK inhibitor I (JI1, EMD, 420099)
+ 15% embryonic stem cell qualified FBS (ES-FBS, 10439-024) + 5% knockout serum
replacement (KSR, 10828028) + 0.1 mM β-mercaptoethanol (21985-023), + 1%
Glutamax (35050-061) + 1% non-essential amino acids (11140-050) + 1% embryonic
stem cell qualified nucleosides (Millipore, ES-008-D). For days 6-8, doxycycline was
removed, ES-FBS concentration reduced to 1%, and KSR concentration increased to 14%
(all other components remained the same). From days 9-14, cells were given chemically
defined medium (CDM) with BMP4: RMPI-1640 (21870-084) + 20 ng/mL BMP4
(Stemgent, 03-0007) + 0.5x N2 (17502-048) + 1x B27 w/o vitamin A (12587-010) +
0.05% BSA fraction V (15260-037) + 0.5% Glutamax + 0.1 mM β-mercaptoethanol.
From day 15 onward, cells were given CDM without BMP4. RW.4 mouse embryonic
stem cells (ATCC), a gift from the Sakiyama-Elbert laboratory, were cultured according
to previously described methods (267).

3.3.4 Cell counts and quantification of beating patches
Phase contrast microscope images (10x magnification) were taken with a CCD
camera (Magnifire, Olympus) and used to perform cell counts at days 0 and 3 for analysis
of initial adhesion and proliferation. Cell counts for three randomly selected images were
averaged to determine the cell density of a given well. For beating patch quantification,
2x images of the entire well were taken by phase microscopy. Wells were then carefully
examined at 4x for beating patches, and these were outlined on the 2x images using
Microsoft Paint. Outlined beating patches filled with white using Adobe Photoshop, and
any bright regions of the image not associated with beating patches were filled with
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black. Images were then thresholded and quantified in Matlab (Mathworks) to determine
the number and size of the beating patches and total beating area of the well. For late
stage cell counts, cells were enzymatically dissociated using trypsin at days 15 (n = 3-6)
and 18 (n = 3-6) and counted using a hemocytometer.

3.3.5 Live-cell calcium imaging
Calcium-sensitive dye Fluo-2 (medium affinity, 10 mM in dimethyl sulfoxide,
excitation/emission 488/515 nm, TefLabs) was mixed (1:1 volume ratio) with 20% (w/v)
Pluronic F-127 (Invitrogen), diluted to 10 µM in DMEM, and applied to cells for 30 min
at 37ºC/5% CO2. Cells were washed three times in PBS and incubated for 15 min in
DMEM to allow complete de-esterification of the Fluo-2. Cells were imaged in Tyrode’s
solution (1.33 mM CaCl2, 1 mM MgCl2, 5.4 mM KCl, 135 mM NaCl, 0.33 mM
NaH2PO4,, pH 7.4) containing 5 mM glucose and 5 mM HEPES by fluorescence
microscopy (IX70, Olympus) using a Magnafire camera (Optronics, 10 frames/second).
The resulting images were analyzed using a custom Matlab script that
tracked fluorescence localization over different time intervals. Noise was removed
through a Prewitt edge detection filter and a series of structuring element filters (2-pixel
lines at 90, 0, then 45 degrees). A 10 x 10 pixel averaging filter was then used to remove
biased pixels that were unrelated to the signal of interest. Finally, activation events were
detected in each pixel by setting a fluorescence threshold. An activation map was formed
by overlaying temporal data with a gradient color scheme.

3.3.6 Quantification of gene expression
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Gene expression was evaluated by quantitative real time RT-PCR using an
Applied Biosystems StepOnePlus or ViiA machine. On day 18 of reprogramming,
cellular RNA was purified with TRIzol reagent (Invitrogen, 15596-026) by following the
manufacturer’s instructions. RNA concentration and quality (260/280 nm absorbance
ratio) was verified using a NanoDrop spectrophotometer. Genomic DNA was removed
and RNA was reverse transcribed to cDNA (10 ng RNA/µL) using the QuantiTect
Reverse Transcription Kit (Qiagen, 205313). Pre-validated primers for mouse GAPDH,
sarcomeric α-actinin (Actn2), cardiac troponin T (Tnnt2), connexin 43 (Cx43), and
Nanog (Nanog) transcripts were obtained from Qiagen (Quantitect Primer Assay).
Forward and reverse primer sequences designed using IDT software and experimentally
validated were β-actin (ActB), sarcomeric α-actinin (Actn2), myosin light chain-atrial
isoform (Mlc2a), potassium/sodium hyperpolarization-activated cyclic nucleotide-gated
channels 1 and 4 (Hcn1, Hcn4), T-box transcription factor Tbx3 (Tbx3), and contactin-2
(Cntn2). Primer sequences are in Supplementary Table S3.1. cDNA was amplified in
triplicate reactions using Quantitect SYBR Green PCR Kit (Qiagen) following
manufacturer’s instructions. Expression levels were normalized to GAPDH or β-actin
internal control genes, or to sarcomeric α-actinin to exclude effects from noncardiomyocytes, using the 2!∆!! method (268).

3.3.7 Immunocytochemistry
For immunocytochemistry, cells were fixed in 4% paraformaldehyde (500
µL/well) for 15 min. Triton-X 100 (Sigma) was diluted 1:1000 in blocking solution
(10% normal goat serum + 1% BSA in PBS) for permeablization (300 µL/well, 30 min at
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room temperature). Sarcomeric α-actinin primary antibody (mouse IgG, Sigma A7811)
was diluted 1:1600 in the blocking solution and applied to the cells (300 µL/well,
overnight at 4ºC). Cells were washed 3x in PBS (5 min each) before incubation in
secondary antibody diluted 1:1000 in blocking solution (300 µL/well, 1 h at room
temperature, Alexa Fluor 594 goat anti-mouse, Invitrogen, A-11005). Cells were washed
3x more in PBS before application of DAPI as a nuclear counterstain (100 ng/mL, 300
µL/well, 30 min at room temperature). Wells were washed once in PBS then imaged in
PBS.

3.3.8 Flow cytometry
At day 18, cells were enzymatically dissociated into a single-cell suspension using
0.25% trypsin-EDTA (Invitrogen), fixed in 1% paraformaldehyde in PBS at 4ºC with
agitation for 20 min, permeablized with 1% saponin (Sigma, S4521) in PBS at 4ºC with
agitation for 20 min, and blocked with 5% normal goat serum (NGS) + 0.5% saponin in
PBS at 4ºC with agitation for 20 min. Sarcomeric α-actinin primary antibody (mouse
IgG, Sigma A7811) was applied to the cells for 30 min at 4ºC with agitation (1:1600 in
2% NGS + 0.5% saponin in PBS). Negative controls had no primary antibody at this step.
AlexaFluor 647 goat anti-mouse secondary IgG (Invitrogen, A21235) was applied to the
cells for 30 min at 4ºC with agitation (1:200 in 2% NGS + 1% saponin in PBS). DAPI
(1:125 in PBS) was applied as a nuclear counterstain. Data were acquired on a
FACSCanto II (BD Biosciences), with at least 10,000 counts per condition. Data were
analyzed using FlowJo software (Tree Star). Negative controls were used to determine
gating parameters.
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3.3.9 Statistics
Two-condition comparisons were made using student’s t-test, whereas multiple
comparisons were made using ANOVA with post-hoc Tukey HSD. In figures, data are
presented as mean ± standard error of the mean. Text references to data are mean ± 1
standard deviation

3.4 Results
3.4.1 Replicating direct reprogramming to cardiomyocyte-like cells on
Matrigel-coated TCPS
To verify that direct reprogramming using OSKM could be replicated in our
hands, we first used adult mouse TTFs to test three possible interpretations of the
published protocol (84) (Fig. 3.1 a). Cells from all groups demonstrated noticeable
morphological changes, notably a decrease in cytoplasm/nucleus ratio by day 6. By day
12, large cell clusters had formed, and were most prevalent in wells from timeline 4 (Fig.
3.1 b). By day 14, beating patches were noted under timelines 3 and 4 only. Timelines 3
& 4 gave similar numbers of beating patches by day 18, with timeline 4 having a slightly
higher number. Given that timeline 4 was also shorter and less complex, it was used in
all subsequent experiments.
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Figure 3.1: Effects of varied induction timelines on adult tail tip fibroblasts. A) Multiple
reprogramming media timelines were tested to clarify the protocols described by Efe et al. Media
with doxycycline (dox) promoted expression of the Yamanaka factors Oct4-Sox2-Klf4-c-Myc
(OSKM) in tail tip fibroblasts (TTFs) derived from transgenic mice. Timeline 4 produced the most
beating clusters. In timeline 4, six days of dox-induced OSKM were coupled with pluripotency
inhibition by Jak-Stat Inhibitor (JI1) in high serum medium. This was followed by three days of
recovery in low serum medium also containing JI1, and then six days of induction of cardiomyocyte
differentiation in chemically defined (no serum) medium containing bone morphogenetic protein 4
(BMP4). Abbreviations: Fibroblast (FB) medium, Knockout (KO) medium, Chemically Defined
(CD) medium, ES-qualified fetal bovine serum (FBS). B) TTFs became smaller and more rounded
under the influence of OSKM, and cells in timeline 4 produced clusters of very small cells by day
12 that ultimately began beating.
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The beating patches demonstrated spontaneously oscillating calcium transients,
which were most prevalent at the outer edges of differentiated clusters or in patches of
cells surrounding the clusters (Fig. 3.2 a-c). Beating patches derived from TTFs stained
positively for striated sarcomeric α-actinin, a cardiac-specific marker (Fig. 3.2 d-e). In
agreement with the location of calcium transients, the most intense α-actinin staining was

Figure 3.2: Characterization of cardiomyocytes directly reprogrammed from adult tail-tip fibroblasts.
Reprogrammed cells formed beating patches visible by phase contrast microscopy (A, day 19). (B) A
time-based map of an activation wavefront from the beating patch in (A) was made using the calciumsensitive dye Fluo-2. The wavefront starts at the right side of the cluster (dark red) and travels through
the perimeter of the cluster (demonstrated by color changes to orange and then yellow). Calcium traces
from individual regions of interest (ROIs) are shown in (C). (D and E) Immunocytochemistry of day 18
TTF-derived cardiomyocytes revealed expression of sarcomeric α-actinin (red) within the beating patches
and in cells attached to the adjacent substrate.
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found in cells surrounding the differentiated clusters.
After demonstrating that the protocol is effective with adult somatic cells, MEFs
harvested from the same mice containing the doxycycline-inducible OSKM cassette were
utilized because they could be expanded to greater numbers in culture and
reprogramming efficiency could be directly compared to the results of Efe et al. At day
21, the number of beating patches generated with MEFs on Matrigel-coated TCPS was
similar to the number previously reported by Efe et al. (245 ± 83 in this study, versus 257
± 17 beating patches per initial 100,000 MEFs seeded).

3.4.2 Adhesion and proliferation of MEFs undergoing reprogramming
on PEG hydrogels
To verify that direct reprogramming could be performed on PEG hydrogels,
MEFs were cultured on surfaces presenting covalently immobilized Matrigel, laminin or
RGD at varied concentrations (referred to as 1x or 5x: for detailed explanations of the
surface concentrations see the methods section or Supplementary Table S3.2). As noted
in previous studies (264), cells did not adhere to PEG surfaces without adhesion
molecules. It is well known that the protein content of Matrigel varies by batch (~60%
laminin, ~30% collagen IV, ~8% entactin and ~2% various growth factors and other
proteins according to product literature) (265). Consistent with this, we found that the
ability of cells to adhere to Matrigel-functionalized PEG was Matrigel batch-dependent
(data not shown). However, cells consistently adhered to laminin-functionalized PEG.
By 24 hours after seeding (day 0 of reprogramming), cell densities were similar on PEGRGD(5x) and TCPS coated with Matrigel or laminin. The densities were statistically
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higher than all other PEG groups and uncoated TCPS (Fig. 3a), indicating higher rates of
initial adhesion and/or proliferation on these surfaces.
Early proliferation dictates the ultimate number of cells available for cardiac
differentiation. To analyze the role of the adhesion molecules on proliferation of cells on
PEG conditions during the first 3 days of OSKM induction, we quantified cell densities at
day 3 and applied the following equation to determine the number of doublings per day:
!

𝑑   =   

𝑙𝑜𝑔! (!! )
!

𝑡

where d = doublings/day, N0 = number of cells at day 0, Nt = number of cells after t days,
and t = number of days (Fig. 3.3 b). Day 3 was chosen as the endpoint because cells on
PEG conditions reached confluency by days 4-5 and thus could not be readily counted.
Rates could not be determined for TCPS conditions as they had reached confluency by
day 3. For PEG conditions presenting RGD alone, the RGD concentration had an effect
on cell proliferation (0.84 ± 0.07 doublings/day for 1x RGD versus 1.14 ± 0.15 for 5x
RGD, p = 0.01 by t-test). PEG conditions presenting laminin alone at 1x or 5x
concentration exhibited proliferation rates similar to the 5x RGD condition.
Over the course of reprogramming, cells on PEG-RGD(5x) continued to
proliferate rapidly compared to other PEG groups, resulting in an extremely high cell
density by day 9 (Fig. 3.3 c). Interestingly, when laminin was added to PEG hydrogels
that also contained 5x RGD, cell densities were noticeably lower. By day 12, the dense
cell layer on PEG-RGD(5x) began peeling off the gel forming compact aggregates at the
edges of the wells (Fig. 3.4 b), and could not be analyzed further. Other conditions
enabled better long-term adhesion, but by day 18, cells of the 1x laminin, 1x RGD and, to
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Figure 3.3: Substrate effects on early stage cell adhesion and proliferation. The culture substrate had
dramatic effects on cell adhesion and proliferation during the first 9 days of the protocol. A) Although
surfaces were seeded equally, the efficiency of cell adhesion and/or proliferation was not the same.
One day after MEF seeding (day 0 of reprogramming), similar cell densities were seen on TCPS
surfaces (red bars) coated with Matrigel or laminin. Cell densities on PEG surfaces did not vary with
low (blue bars) versus high (green bars) concentrations of adhesion molecules (#not statistically
different at α=0.95 by Tukey’s HSD test), but some conditions were lower than the coated TCPS groups
(* p<0.05 versus TCPS-Mat(1x) and TCPS-lam(1x)) B) Cell counts from PEG hydrogels containing
only RGD or only laminin were used to calculate proliferation rates over days 0-3. The proliferation
rate was positively influenced by RGD concentration (*p<0.05 by t-test), but not laminin-1
concentration. C) When RGD was used alone at 5x (lower left), an exceptionally high cell density was
noticeable by phase microscopy by day 9. Densities were not as high on PEG-RGD(1x) or any PEG
group where laminin was included.
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a lesser degree, 5x laminin conditions had also begun peeling off the gel in isolated areas.
Long-term adhesion problems were completely resolved by using both laminin and RGD.
No long-term adhesion issues were noted on any TCPS conditions.
Cells were counted by hemocytometer on days 15 and 18 for TCPS-Mat(1x),
PEG-lam(5x), PEG-lam(5x)-RGD(1x), and PEG-lam(5x)-RGD(5x) to assess
proliferation at a later stage of the reprogramming timeline. The cell density between the
two days was not different for any condition, suggesting a decrease in proliferation. This
finding is consistent with the decrease in progenitor marker (Mesp1 and Isl1) expression
reported by Efe et al. for that time frame, which suggests a transition from a proliferative
progenitor to a less proliferative immature cardiomyocyte (84). Counts also did not vary
between PEG-lam(5x) with 1x versus 5x RGD. Counts were therefore pooled to increase
the number of samples for a statistical analysis of late stage cell density (n=6-12). PEGlam(5x)-RGD(1x or 5x) gels had a ~25% increase in cell density compared to the original
condition used in Efe et al., or PEG-lam(5x) without RGD (Fig. 3.4 a, p<0.05 by
ANOVA with post-hoc Tukey HSD). Cell density on PEG-lam(5x) with RGD increased
by a factor of 136.2 ± 23.7 compared to initial MEF seeding density. Densities on PEGlam(5x) without RGD and TCPS-Mat(1x) increased by factors of 109.1 ± 20.5 and 108.3
± 16.7, respectively.
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Figure 3.4: Cell density and morphology at late stages of reprogramming protocol. Addition of RGD to
PEG hydrogels boosted cell proliferation. A) Cells were trypsinized and counted by hemacytometer at
days 15 and 18. Within the same condition, the cell density did not vary by day. Counts also did not vary
between PEG-lam(5x) with 1x or 5x RGD. Counts from these conditions were therefore pooled to
increase the number of samples for statistical analysis (n = 6-12). PEG-lam(5x) gels with RGD yielded
~25% more cells per square centimeter than TCPS-Mat(1x) or PEG-lam(5x) without RGD (*p<0.05 by
ANOVA with post-hoc Tukey HSD test). B) Phase contrast images were stitched together to give a
macroscopic view of the individual wells. Without laminin, cells on the RGD(5x) gel rolled off the plate
forming a large clump at the edge of the well (white arrow). On gels with laminin, more clusters were
seen on gels that also presented RGD at 5x. Clusters on gels with 5x laminin but no RGD had a more
spread morphology than those on gels presenting RGD (bottom image).
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3.4.3 Functional assessment of direct reprogramming to
cardiomyocyte-like cells on PEG surfaces
Many of the laminin receptors are upregulated during the first 3 days of OSKM
reprogramming, whereas collagen receptors are downregulated (253). Thus, we
hypothesized that reprogramming would be equally as efficient on laminin versus
Matrigel. Numbers of differentiated clusters were visibly increased on PEG-lam(5x)RGD(5x) compared to PEG-RGD(1x), PEG-lam(1x)-RGD(1x) and PEG-lam(5x)RGD(1x) (Fig. 3.4 b).
Beating assays provide a simple yet well-accepted method for initially estimating
cardiac reprogramming efficiency (32, 84, 269-272). On TCPS (Fig. 3.5 a, red columns,

Figure 3.5: Effects of culture substrate on cell beating at day 18 of reprogramming. The extent of cell
beating, quantified manually by phase contrast microscopy, was influenced by the culture substrate. A)
Beating patches are defined as synchronously contracting. PEG hydrogels with high surface densities of
adhesion molecules (green bars) had greater numbers of beating patches than gels with low surface
densities (blue bars) or any TCPS surface (red bars) (*p<0.05 versus PEG-lam(5x)-RGD(5x); #p<0.05
against PEG-lam(5x) by Tukey’s HSD test). The numbers of beating patches on TCPS surfaces (red bars)
were similar regardless of adhesion molecule type or concentration. Unlike the PEG gels, it was not
possible to increase beating on TCPS by increasing the laminin concentration. B) PEG conditions
presenting laminin at 5x (with or without 5x RGD) also had greater coverage of beating cells than all
TCPS conditions or PEG-lam(1x) (*p<0.05 by Tukey’s HSD test).
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Matrigel and laminin-1 coatings led to similar numbers of beating patches per cm2 at day
18 (9.04 ± 3.05 versus 9.44 ± 2.42 respectively; p = 0.71 by t-test). When PEG was
functionalized with 1x RGD, 1x laminin, or both (Fig. 3.5 a, blue columns), beating patch
numbers were similar to the TCPS conditions. A non-significant increase was noted
when PEG-lam(1x) gels also presented 5x RGD. This trend was also seen on PEGlam(5x) gels presenting 1x or 5x RGD (Fig. 3.5 a, green columns). PEG-lam(5x)RGD(5x) had more beating patches than all TCPS conditions and PEG with lower
adhesion molecule concentrations. PEG-lam(5x) (no RGD) also promoted more beating
than several of these groups, including the PEG-lam(1x) (no RGD) condition. Increasing
laminin concentration from 1x to 5x on TCPS did not result in more beating, suggesting
that adsorbed amounts of laminin were already near maximal at 1x solution concentration.
On TCPS, laminin saturates around 850 ng/cm2 (273), which is 13.4 and 67.1 times lower
than our 1x and 5x concentrations. Therefore, the actual density of the laminin layer
adsorbed on TCPS is likely similar for our 1x and 5x concentrations. Similar trends were
noted when considering the total beating area instead of the number of beating patches
(Fig. 3.5 b). Reprogramming efficiency on Matrigel-functionalized PEG was difficult to
assess given the aforementioned adhesion inconsistencies, and Matrigel-functionalized
PEG gels were not studied further.
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3.4.4 Gene and protein expression of directly reprogrammed cultures
Gene expression in day 18 reprogrammed cells was evaluated by reverse
transcription quantitative real-time PCR (qRT-PCR) (Fig. 3.6 a-b). Similar to what was
seen in the beating patch counts, gene expression levels from PEG hydrogels with 5x
laminin and 1x, 5x, or no RGD were statistically similar. Likewise, no differences were

Figure 3.6: Effects of culture substrate on gene expression at day 18 of reprogramming. A) Levels of
cardiac (Actn2, Tnnt2, Cx43) and pluripotency (Nanog) markers were analyzed by quantitative real time
RT-PCR. Markers were normalized to the GAPDH internal control gene. TCPS condition levels are scaled
to 1 to present fold induction. Levels of Actn2 were higher on PEG-lam(5x) substrates (all RGD levels,
green bars) than TCPS (all laminin levels, red bars) (*p <0.05 by t-test). Nanog levels were decreased
(*p<0.05 by t-test). N = 9-18 wells. Samples were pooled to increase the number of samples, with
measurements for individual substrates presented as supplementary materials. No statistical differences or
trends were found between any of the pooled conditions. B) Expression levels of cardiac sub-type genes
were normalized to sarcomeric α-actinin (Actn2) to exclude effects from non-cardiomyocytes. Expression
level of the atrial marker Mlc2a stays constant, while markers for cardiac nodal and conduction cell
phenotypes (Hcn1, Hcn4, Tbx3, Cntn2) are generally downregulated on PEG-lam(5x) conditions when
compared to TCPS-Mat(1x) (the condition in Efe et al.). TCPS+Mat(1x) (n=3) is normalized to 1 to
present fold change of the PEG-lam(5x) conditions. No statistical differences or trends were seen in PEGlam(5x) gels presenting 5x RGD (n=3) or no RGD (n=3), so the conditions were pooled for the purpose of
statistical testing (n=6). (*p<0.05 by Student’s t-test.)
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seen in expression levels on TCPS with 1x or 5x laminin (supplementary Fig. S3.1). Due
to inherent high variability in qRT-PCR, data from similar conditions were pooled to
increase sample numbers for statistical analysis. Results for each surface are presented
individually as supplementary materials (Fig. S3.1).
Cells reprogrammed on PEG hydrogels presenting 5x laminin (with varied levels
of RGD) had higher sarcomeric α-actinin (Actn2, 1.7-fold, p =0.03) levels than those
reprogrammed on TCPS conditions (with varied levels of laminin) (Fig. 3.6 a). Levels
were also higher for cardiac troponin T (Tnnt2, 1.3-fold, p =0.08) and connexin 43 (Cx43,
1.6-fold, p= 0.06), although these changes were not statistically significant. Nanog
expression was lower on 5x laminin PEG groups (with all levels of RGD) than on TCPS
groups with all laminin concentrations (2.4-fold decrease, p= 0.0001), and the pooled 5x
laminin PEG groups were ~700 fold lower than Nanog levels of RW.4 mouse embryonic
stem cells.
Cardiomyocyte-like cells resulting from direct reprogramming strategies have not
been well characterized with regard to the cardiomyocyte subtype generated, however,
the ability to generate different types of cardiomyocytes will likely have important
therapeutic consequences. We compared expression of atrial and conduction-enriched
genes on PEG-lam(5x) (with and without 5x RGD) to the original condition described in
Efe et al. (TCPS-Mat(1x)). Markers for conduction and nodal cell phenotypes (Hcn1,
Hcn4, Tbx3, and Cntn2) were normalized to α-actinin to take into the account the
differences we see in reprogramming efficiency in these conditions (Fig. 3.6 b).
Interestingly, expression of conduction and nodal genes was generally higher on the
TCPS-Mat(1x) condition, suggesting that there may be subtle but important roles that the
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microenvironment plays in the reprogramming processes to generate these different
subtypes of cells.
Immunocytochemistry was used to quantitatively compare cardiac marker
sarcomeric α-actinin expression on PEG conditions. Actinin/DAPI-positive pixel ratios
for PEG hydrogels presenting 5x laminin with varied RGD concentration were double
those presenting 1x laminin with varied RGD concentration (0.02 ± 0.01 versus 0.01 ±
0.01, respectively. p <0.05 by t-test) (Fig. 3.7 a-c). Data for individual conditions can be
found in supplementary Fig. S3.2.

Figure 3.7: Immunocytochemical comparison of cardiac marker expression on PEG conditions with 1x
versus 5x laminin. Wells were stained for the cardiomyocyte marker sarcomeric α-actinin, with DAPI
as a nuclear counterstain. A) The number of α-actinin positive pixels was normalized to the number of
DAPI positive pixels for each well. PEG conditions presenting laminin at 5x had a higher αactinin/DAPI ratio than conditions presenting laminin at 1x (*p<0.05 by t-test). (B and C) sample
images from the quantitative analysis performed in (A). Samples were pooled to increase the number of
samples, with measurements for individual substrates presented as supplementary materials.
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Reprogramming efficiency was measured by flow cytometry for sarcomeric αactinin (Fig. 3.8 a). No significant differences were found between any of the PEGlam(5x) groups, though averages for groups containing RGD were slightly higher. The
percentage of sarcomeric α-actinin-positive cells was 1.72-fold higher on PEG-lam(5x)RGD(1x or 5x) compared to TCPS-Mat(1x) (Fig. 3.8 b, 6.35 ± 0.69% versus 3.70 ±
1.03%, p<0.05 against TCPS-Mat(1x) by ANOVA with post-hoc Tukey HSD test).

Figure 3.8: Quantification of α-actinin expression by flow cytometry. PEG-lam(5x) gels with RGD
promoted higher efficiency reprogramming. A) Histograms for fluorescence intensity of sarcomeric
α-actinin IgG negative controls (black) versus stained cells (grey) demonstrated well-separated peaks
between stained cells and the negative control. At least 10,000 events are presented per condition. B)
The average percentage of α-actinin positive cardiomyocytes in PEG-lam(5x) gels containing RGD
was ~1.72-fold higher than the condition originally described in Efe et al. (*p<0.05 against TCPSMat(1x) condition by ANOVA with post-hoc Tukey-HSD). C) Combined with the proliferation data,
the increased efficiency gave greater numbers of cardiomyocyte on PEG-lam(5x) gels containing
RGD than PEG-lam(5x) gels without RGD or TCPS-Mat(1x) controls (*p<0.05 by ANOVA with posthoc Tukey HSD).
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Coupled with the late-stage cell density data (Fig. 3.4 a), the PEG-lam(5x) conditions
containing RGD yielded 7.73 ± 0.78 cardiomyocyte-like cells per originally seeded MEF,
which is ~2-fold higher than TCPS-Mat(1x) and ~1.5-fold higher than PEG-lam(5x)
without RGD (Fig. 3.8 c, p<0.05 against both conditions by ANOVA with post-hoc
Tukey HSD).

3.5 Discussion
In this study, we demonstrated that the efficiency of direct reprogramming to
cardiomyocyte-like cells can be nearly doubled by using custom-tailored PEG culture
substrates. By using protein-resistant PEG, we were able to specifically probe the effects
of covalently bound ligands on direct reprogramming without the confounding effects of
adsorbed serum proteins. Ultimately, this led to the development of a culture surface that
produced about twice as many cardiomyocyte-like cells as the originally described
substrate. This type of precise control over microenvironment definition is a promising
frontier in the field of undifferentiated PSC expansion (274). Global gene expression
analyses have also allowed researchers to specifically tailor media to meet the needs of
pluripotent stem cells (251, 252), and this strategy should have a similar impact on the
design of materials to control cell microevironment. To date, many laboratories still use
Matrigel to trigger integrin signaling pathways and define the cell microenvironment.
Replacement of Matrigel with synthetic surfaces (275, 276), biologically inspired
peptides (277-279) or purified whole proteins has allowed or enhanced PSC expansion in
multiple studies. When ECM components are analyzed individually, laminin (100, 280),
vitronectin (102), and E-cadherin (281) have shown to promote undifferentiated human
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PSC expansion on TCPS, while fibronectin and collagen IV have been reported to cause
their differentiation (100). Interestingly, while the laminin-111 isoform (used in this
study) allows undifferentiated expansion of human PSCs (280), it has also caused
differentiation of mouse PSCs (282), suggesting differences in integrin
expression/signaling/ligand interactions between species.
While many groups are studying substrate designs for differentiating PSCs to
cardiomyocytes, the cells of this protocol start as “pre-iPSCs”, which are phenotypically
different from iPSCs (283). The cardiac direct reprogramming literature has not yet
examined the importance of ECM signaling, making comparisons between various
protocols rather complicated. As mentioned earlier, we began with the insight that Koche
et al. (253) provided into pre-iPSC integrin expression 3 days after OSKM induction.
Taking that study into account, we designed the PEG substrates to have a high
concentration of laminin (without the collagen IV that is present in Matrigel). However,
laminin alone was not sufficient to support cell adhesion to PEG during the full 18 days
of our protocol, possibly due to matrix metalloproteinase degradation. Because RGDbinding integrins were not strongly affected by OSKM induction (253), we incorporated
RGD to promote long-term cell adhesion. While the presence of RGD positively affected
cell proliferation on PEG hydrogels, its effects on cardiac gene or protein expression
were not significant.
Recently, MacLellan and colleagues demonstrated that the timing of ECM protein
presentation is important for cardiac maturation. First, they performed an
immunohistochemical analysis of developing mouse and human hearts. This showed
distinct ECM differences between stem cell niches (mostly collagen IV and laminin) and
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the surrounding myocardium (mostly collagen I and fibronectin) into which the maturing
cells migrate (124). Using this information, they differentiated mouse ESCs on TCPS
and found upregulation of Flk1 (a VEGF receptor but also a cardiac progenitor marker)
and ultimately higher expression of the α-MHC (cardiomyocyte marker) on collagen IV
and laminin coatings (as compared to collagen I or fibronectin). By isolating Flk1+
progenitor cells and re-plating them onto new ECM protein coatings, they showed that
fibronectin was better at promoting cell cardiomyocyte maturation than collagen IV or
laminin. Interestingly, Kamp and colleagues have demonstrated that cardiogenesis from
iPSCs is robustly increased by providing “Matrigel overlays” at several timepoints during
differentiation (284), further indicating the importance of timing in ECM presentation.
We expect that by providing ECM proteins to match the timing of integrin expression
during direct reprogramming, we could further improve cardiac cell differentiation
efficiency.
Hydrogel substrates allow manipulation of multiple variables beyond what was
examined in this study. In addition to ligand type and density, one could also study
effects of hydrogel chemistry, nanotopography, degradation/remodeling, and elastic
modulus. Here, we compared effects of two substrates that differ drastically in stiffness.
The storage modulus of this type of gel is ~7 kPa (200), which is similar to developing
heart tissue (164) and has been shown to support embryonic cardiomyocytes (109) and
ESC differentiation to cardiac progenitors (159) better than substrates of drastically
different stiffnesses. While the adhesion protein density dependence (seen only on PEG)
confirmed that integrin-dependent pathways are in some part responsible for the
improvement, it is possible that the heart-like elastic modulus also played a role. Further
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studies should be undertaken to examine the interplay of these two factors in greater
detail.
To compare our data to Efe et al., we terminated our studies at day 18. However,
many factors are known to affect the maturation of PSC-derived cardiomyocytes,
including duration in culture (34) embryoid body size and culture condition (285, 286),
and growth factor signaling (287). Electrophysiological analysis and global gene
expression analyses could be used to assess the maturity at timepoint and later time points
(288). Based on the aforementioned studies, we expect that the mechanical and integrinactivation properties and could be adjusted to fine-tune specific cardiac phenotypes
yielded by the protocol.
Of the currently reported cardiac direct reprogramming strategies, we chose to
work with the Efe et al. protocol for several reasons, many of which are also outlined in a
recent review by Morris and Daley (74). The ability to expand cells in culture is
important for treating large myocardial injuries. In the Ieda et al. method, cells are
converted directly to non-proliferating cardiomyocytes. In the Efe et al. protocol, the
cells travel through a proliferative progenitor state, yielding greater numbers of
cardiomyocytes (84). Indeed, in this study we were able to double the number of
cardiomyocytes produced, in part due to enhanced proliferation on the PEG-lam(5x) gels
containing RGD. The progenitors formed by this protocol may also have vascularization
potential (84, 85). Indeed, brief OSKM induction combined with VEGF stimulation has
separately been shown to directly reprogram human pre-iPSCs to endothelial cells (289).
Finally, the Efe et al. method reduces the time to beating (~2 weeks versus 4-5 weeks)
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compared to the Ieda et al. method, which may be important clinically as the cardiac
remodeling cascade starts immediately following infarction (86, 87).
On the other hand, several groups have reported in vivo infarction scar
reprogramming since their original in vitro paper (77, 80-82). This feat has not yet been
performed using the Efe et al. protocol, and it can be argued that teratoma risks are higher
for the Efe protocol because the cells are more likely to revert to a pluripotent state.
However, the OSKM induction in this protocol is transient, and further studies may allow
development of methods that ameliorate the risk of teratoma formation (290). In this
study, we were able to reduce the already low Nanog expression 2.3-fold by using
defined substrates. This leads us to believe that it will ultimately be possible to prevent
the formation of pluripotent cells. However, it will also be important to demonstrate the
effects of cell microenvironment on the efficiency of the Ieda protocol.
Some groups have reported difficulties reproducing the Ieda et al. protocol (291),
and to our knowledge no studies have yet been published using the Efe et al. protocol.
Robust induction and proper stoichiometry of the reprogramming factors are highly
important for achieving reprogramming using the Ieda et al. protocol (292) and
presumably the Efe et al. protocol as well. This can be difficult to achieve using viral
induction methods. The availability of mice carrying a doxycycline-inducible
polycistronic OSKM cassette (263) eliminated variability between experiments,
providing an excellent cell source for probing cell-material interactions in direct
reprogramming. While demonstration of direct reprogramming in human cells is more
clinically relevant, the genetic homogeneity of cells from transgenic mice is a powerful
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advantage, especially when differences in microenvironments may change a number of
measures by less than two-fold.
The original publication also reported ~40% cTnT-positive cells, which was an
additional reason we initially selected this protocol over the others. However, we found
cells cultured on TCPS-Mat(1x) to be only ~4% α-actinin-positive. This discrepancy
may be attributed to one or several of the following: 1) temporal variations in the
expression of cTnT versus α-actinin during reprogramming, 2) differences in the
robustness of the cTnT antibody versus the α-actinin antibody, 3) subtle differences in
culture protocols between laboratories, or 4) variations in flow cytometry analysis
between laboratories.
The field of cellular reprogramming has progressed at lightning speed since the
discovery of induced pluripotency in 2006 (28). Unlike traditional PSC differentiation
strategies, direct reprogramming has the potential to eliminate the need for in vitro cell
expansion, differentiation, and cell transplantation. Biomaterials that control the cellular
microenvironment and eliminate confounding signals caused by adsorbed serum proteins
have the potential to enhance our understanding of the requirements for both in vitro and
in vivo direct reprogramming.

3.6 Conclusions
PEG culture substrates were designed to match integrin expression during the
initial stages of OSKM-mediated direct reprogramming of fibroblasts to cardiomyocytelike cells. Through a combination of increased reprogramming efficiency and increased
proliferation, PEG hydrogels presenting high concentrations of laminin and RGD peptide
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yielded twice as many cardiomyocyte-like cells as the originally reported substrate
(Matrigel-coated TCPS). RGD peptides enabled better cell adhesion, stimulated
proliferation, and did not impede reprogramming. The general methodology, using gene
expression to guide materials design, may be applicable to a wide variety of
reprogramming strategies.
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3.8 Supplementary Tables and Figures
Table S3.1: Primer sequences. Primer sequences used in the analysis of cardiac sub-types.

Table S3.2: Substrate conditions table. Surface densities and method of binding for adhesion
molecules on various substrates. *Matrigel and laminin-1 surface densities (1x) are based on
approximate Matrigel surface protein concentration reported in Efe et al. **RGD surface density (1x)
based on the approximate RGD surface density of PEG hydrogel microspheres in Smith et al.
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Figure S3.1: Expanded gene expression data. Sarcomeric α-actinin (Actn2), Cardiac troponin T
(Tnnt2), Connexin 43 (Cx43), and Nanog (Nanog) gene expression levels were were acquired by
quantitative real-time RT-PCR and normalized to those of the internal control gene GAPDH. *p<0.05
by Tukey’s HSD test against the undifferentiated MEF control.
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Figure S3.2: Immunocytochemical comparison of cardiac marker expression on PEG gels
Wells were stained for cardiomyocyte marker sarcomeric α-actinin and DAPI as a nuclear
counterstain. The number of α-actinin positive pixels was normalized to the number of DAPI positive
pixels for each well. *p<0.05 against PEG-RGD(1x) by Tukey’s HSD test.
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CHAPTER 4
Effects of 3D microenvironmental variables on
direct reprogramming of mouse fibroblasts to
cardiomyocyte-like cells
4.1 Abstract
Direct reprogramming to cardiomyocytes, or conversion of somatic cells to
cardiomyocytes without going through the pluripotent state, has so far only been
investigated using two-dimensional culture substrates. However, optimizing threedimensional culture protocols will bolster the scalability for clinical use. In this study,
we analyze the effects of materials, topography, diffusion, and remodeling on a 3D direct
reprogramming protocol adapted from Efe, et al. (Nature Cell Biology, 2011, 13:215).
Compared to 2D culture, cardiac gene expression (Actn2 and Tnnt2) was downregulated
when cells were reprogrammed within 3D PEG microsphere scaffolds and 3D collagen
scaffolds but was not statistically different for 3D collagen-PEG microsphere hybrid
scaffolds. Sarcomeric α-actinin expression was lowest within PEG microsphere scaffold
interiors, suggesting that diffusion and remodeling restrictions may be at play. Cardiac
gene expression was also downregulated when cells were cultured on 2D layers of PEG
microspheres as compared to flat 2D PEG surfaces, suggesting that the topography of the
microspheres may be inhibiting efficient cardiac reprogramming. These analyses provide
the groundwork for designing 3D scaffolds to permit high efficiency direct
reprogramming to cardiomyocytes, particularly with regards to substrate topography and
cellular remodeling capacity.
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4.2 Introduction
Two-dimensional (2D) cell culture models have led to countless medical
breakthroughs. However, the clinical transition of autologous cell transplantation
research will demand a scalability that 2D culture cannot easily provide. For example, if
all of the cells of the average human heart were to be cultured in 2D, it would require
~3,5002 feet of culture area. Three-dimensional (3D) culture techniques address
scalability, but many differentiation protocols are still being optimized for 2D culture,
including those related to the new and rapidly growing field of direct reprogramming to
cardiomyocytes (75, 76, 82, 84). Direct reprogramming is the process by which a fully
differentiated cell (i.e. a skin fibroblast) can be converted to another cell type without
entering a pluripotent state. In this study, we focus on the protocol initially described by
Efe et al., which is faster and more efficient than taking somatic cells through induced
pluripotency before reaching cardiomyocytes (84). Like other direct reprogramming
protocols (75, 76, 82), it has only been optimized for 2D culture.
Cells adhered to 3D materials exhibit dramatic differences compared to their 2D
counterparts (119-123). Adhesion-mediated processes begin at integrin receptors in focal
adhesions, and are transmitted through the cell via mechanically-sensitive cytoskeletal
networks (293-296). DeSimone (297), Guilak and colleagues have recently provided
thorough reviews on adhesion mediated processes, which are well known to affect cell
division, apoptosis, migration, and differentiation. Various groups have demonstrated the
importance of substrate mechanical properties (108, 109, 159), substrate topography (101,
107), and the shape of adhesive areas (110, 298, 299) on cytoskeletal morphology and
cell behavior. Recently, Schenke-Layland et al. investigated specific properties of the
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natural cardiac stem cell niche, and designed culture substrates accordingly. They found
that differentiation of mouse embryonic stem cells (ESCs) to cardiac progenitors was
enhanced in a 3D electrospun scaffold compared to routine, flat 2D culture (124).
Differentiation to cardiac progenitors was further enhanced when the scaffolds were
coated with type IV collagen and gelatin as opposed to gelatin alone.
We have previously demonstrated that direct reprogramming efficiency can be
increased using 2D poly(ethylene glycol) (PEG) substrates that present precise
concentrations of adhesion molecules instead of 2D tissue culture polystyrene (TCPS)
substrates (300). Separately, we have also demonstrated that modular PEG microspherebased scaffolds enable HL-1 cells to retain certain aspects of their cardiomyocyte
phenotype for long periods in culture (266). In this study, we encapsulate cells in PEG
microsphere scaffolds, collagen scaffolds, or collagen-PEG microsphere hybrid scaffolds,
and compare the 3D materials in terms of direct reprogramming efficiency. We also
examine the effects of dimension (2D vs. 3D), diffusion into the 3D scaffold, and
topography of the culture substrates using PEG materials.
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4.3 Materials and Methods:
4.3.1 Cell culture and direct reprogramming
The direct reprogramming protocol used to generate cardiomyocytes is adapted
from Efe et al. (84). Extended versions of this protocol, including validation with adult
somatic cells, are published elsewhere (84, 266). All experiments in this study used
mouse embryonic fibroblasts (MEFs) homozygous for doxycycline-inducible Yamanaka
factors (Oct4, Sox2, Klf4 and c-Myc) (28, 263). Animal protocols were approved by
Washington University Institutional Animal Care Use Committee. A schematic of the
culture timeline is shown in Fig. 4.1. MEFs were plated onto 2-dimensional substrates
(3,600/cm2) or seeded into 3-dimensional scaffolds one day prior to beginning the

Figure 4.1: Direct reprogramming media and supplements timeline. The direct reprogramming
protocol was adapted from Efe et al. (and verified in Smith et al.). Six days of dox-induced OSKM
were coupled with pluripotency inhibition by Jak-Stat Inhibitor (JI1) in high serum medium. This
was followed by three days of recovery in low serum medium also containing JI1, and then six days of
induction of cardiomyocyte differentiation in chemically defined (no serum) medium containing bone
morphogenetic protein 4 (BMP4). Abbreviations: Fibroblast (FB) medium, Knockout (KO) medium,
Chemically Defined (CD) medium, ES-qualified fetal bovine serum (FBS).
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protocol (day -1). Seeding densities were 10 million/mL for PEG scaffolds (unless
otherwise noted) and 1 million/mL for collagen-containing scaffolds (lowered to account
for cell density increases upon collagen gel compaction (301)). Reprogramming
commenced the following day (day 0), and media was changed every 24-48 hours. From
days 0-5, cells received knockout DMEM (KO DMEM, 10829018) + 2 µg/mL
doxycycline (made fresh for each experiment, Sigma, D9891) + 0.5 µM JAK inhibitor I
(JI1, EMD, 420099) + 15% embryonic stem cell qualified FBS (ES-FBS, 10439-024) +
5% knockout serum replacement (KSR, 10828028) + 0.1 mM β-mercaptoethanol (21985023), + 1% Glutamax (35050-061) + 1% non-essential amino acids (11140-050) + 1%
embryonic stem cell qualified nucleosides (Millipore, ES-008-D). For days 6-8,
doxycycline was removed, ES-FBS concentration reduced to 1%, and KSR concentration
increased to 14% (all other components remained the same). From days 9-14, cells were
given chemically defined medium (CDM) with BMP4: RMPI-1640 (21870-084) + 20
ng/mL BMP4 (Stemgent, 03-0007) + 0.5x N2 (17502-048) + 1x B27 w/o vitamin A
(12587-010) + 0.05% BSA fraction V (15260-037) + 0.5% Glutamax + 0.1 mM βmercaptoethanol. From day 15 onward, cells were given CDM without BMP4. Cells in
scaffolds received 3 mL of media/day, while 2D cultures were given 1 mL/well. RW.4
mouse embryonic stem cells (ATCC), a gift from the Sakiyama-Elbert laboratory, were
cultured according to previously described methods (267).

4.3.2 Materials
For 2D control conditions, experiments were performed in 24-well plates. For
PEG substrates, plates were first treated with a plasma cleaner (Harrick Plasma) set to
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medium (350 mTorr for 5 min) to reduce meniscus formation in the wells during gel
formation. Plates were then UV-sterilized for 30 min and gel precursor solutions were
added immediately. PEG derivatives were synthesized as previously described (213, 214,
264). For gel fabrication, PEG8-Vs and PEG8-Am solutions (both 20% w/v in PBS, pH
7.4) were sterile-filtered (0.22 µm filter) and diluted in 0.03 M NaOH in PBS (pH 8.75;
NaOH enhanced reaction kinetics and further reduced meniscus formation) for a final
PEG concentration of 12.43% (w/v). The precursor mix was aliquoted at 200 µL/well
and allowed to crosslink in a humidified incubator (37ºC) for 1-2 days.
On 2D surfaces, protein and peptide surface concentrations are given as 1x or 5x
as previously reported (300). When referring to Matrigel (BD Biosciences, 356234) or
laminin-1 (Sigma, L2020), 1x is the approximate protein concentration of Matrigel used
in Efe et al. (11.4 µg/cm2). The 1x concentration of laminin was also set to 11.4 µg/cm2.
When referring to the RGD peptide, 1x (354 µg/cm2) was empirically determined to
promote robust cell adhesion and reprogramming on 2D substrates (300). For
functionalization with Matrigel or laminin-1, protein stocks were first diluted to 108.3
(1x) or 541.5 µg/mL (5x) in PBS. If RGD peptide (GCGYGRGDSPG, Genscript) was
included, it was diluted in the same tube as the protein at 3.36 (1x) or 16.82 (5x) mg/mL.
Each well received 200 µL of protein/peptide solution. The pre-formed PEG hydrogels
were incubated with the protein/peptide mixtures overnight at 37ºC to permit the covalent
Michael-type reaction to occur. For TCPS conditions, (non-plasma treated) 24-well
plates were incubated at room temperature for 1 h to permit protein adsorption (according
to Matrigel product literature).
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Microspheres were fabricated as previously described (199, 200, 266). Briefly,
20% (w/v) PEG8-VS and PEG8-Am were mixed (either 2:1 or 1:1 PEG8-Vs:PEG8-Am)
and pre-reacted for 70% of the total gel time needed to reach gel point. RGD (1 or 5 mM,
sequence GCGYGRGDSPG, Genscript) was added to the prereacted solution and reacted
at 37ºC for an additional 30 min. The pre-reacted solution was diluted to a final
concentration of 2% PEG and ~0.5 M Na2SO4 and brought to 37ºC to induce phase
separation. The Na2SO4 concentration needed to achieve cloud point is sensitive to
fluctuations in pH, temperature, Na2SO4 and PEG stock concentrations (199), and should
be empirically verified any time a new stock solution is introduced. PEG was reacted in
the phase-separated state for 45 min (for 1:1 OVs:OAm microspheres) or 55 min (for 2:1
OVs:OAm) to form microspheres, Na2SO4 solution was replaced with PBS via
centrifugation (14,000 RCF for 2 min), and microspheres were washed once more then
resuspended in PBS. Post-swelling microsphere diameters were 10.2 µm for 1:1
OVs:OAm and 20.1 µm for 2:1 OVs:OAm. Microsphere volumes were determined by
measuring the total volume of solution after the addition of 500 µL of PBS.
For reaction of adhesion proteins to remaining OVs groups on microsphere
surfaces, microspheres were incubated overnight at 37ºC on a slow, horizontal rocker
with laminin in PBS at a 2:5 microsphere:laminin solution volume ratio. The
concentration of laminin reacted to the microspheres was adjusted to approximate the
equivalent protein spacing as the cells experienced in 2D:
[𝑙𝑎𝑚]!! =   

[𝑙𝑎𝑚]!!

!

So 1x (11.4 µg/cm2) in 2D becomes 38.5 µg/mL microspheres in 3D. To fluorescently
label microspheres, 1 µL of Dylight-633 NHS Ester (10 mg/mL, Thermo Scientific,
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46414) was added per microliter of pre-formed 2:1 OVs:OAm microspheres. To create
2D microsphere layers on TCPS, 20 µL of pre-functionalized microspheres in PBS were
suspended per well of a 24 well plate, and centrifuged at 300 RCF for 15 min.
Microspheres remained adhered to the plate by electrostatic interactions throughout the
18 day protocol, forming a continuous layer upon which cells could be cultured.
Encapsulation of cells during the crosslinking of PEG microsphere scaffolds has
also been described elsewhere (266). Pelleted MEFs were resuspended in 50 µL of
warmed 20% dextran (Mr = 100,000, Sigma Aldrich, 09184) in DMEM, and this solution
was used to resuspend a microsphere pellet of equal volume (50 µL) in a 1.5 mL
Eppendorf tube. The tube was centrifuged (500g for 3 min) to promote separation of the
PEG and the dextran, and incubated at 37ºC for 1 hr to allow microsphere-to-microsphere
crosslinking around the MEFs. Cylindrical, crosslinked scaffolds (~5.9 µm in diameter,
1.8 µm in height) were then transferred to 35 mm diameter non-tissue culture treated
plastic petri dishes and routine cell culture techniques commenced (3 mL media/day).
For collagen-based scaffolds, 60 µL of collagen (5 mg/mL, Cultrex Rat Tail
Tendon Collagen I, R&D Systems, 3447-020-01) was diluted on ice in 73.6 µL sterile
double distilled water, 15 µL of 10X concentrated DMEM, and 1.4 µL of 0.34 M NaOH.
Pelleted MEFs were quickly resuspended in 50 µL of serum free DMEM and added to
the collagen mixture for a final collagen concentration of 1.5 mg/mL. For collagen-PEG
hybrid gels, 20 µL of pre-functionalized microspheres were added with the cells.
Collagen was then carefully pipetted onto a 35 mm non-tissue culture treated plastic petri
dishes. After crosslinking at 37ºC for 1 hr, gels were carefully detached from the surface
and routine cell culture techniques commenced (3 mL media/day).
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4.3.3 Quantification of gene expression
Gene expression was evaluated by quantitative real time RT-PCR using an
Applied Biosystems StepOnePlus machine. On day 18 of reprogramming, cellular RNA
(n=6 samples per condition) from 2D samples was purified with TRIzol reagent
(Invitrogen, 15596-026) by following the manufacturer’s instructions. For 3D samples,
each scaffold was homogenized (Tissue Miser, Fisher Scientific) on ice in a 50 mL
centrifuge tube containing 2.6 mL of ice cold TRIzol and 137 µL of glycogen (5 mg/mL,
Invitrogen, AM9510) for 1 min. The suspension was divided into two 1.5 mL Eppendorf
tubes and centrifuged at 4ºC for 2 min at 12,000 RCF to remove solid material. The
supernatant was transferred to two new 1.5 mL Eppendorf tubes, and routine TRIzol
extraction methods ensued. The final RNA pellet was resuspended in 12 µL of 1 mM
sodium citrate buffer (pH 6.4, Invitrogen, AM7000). RNA concentration and quality
(260/280 nm absorbance ratio) were verified using a NanoDrop 2000 or Implen
Nanophotometer P-Class. Genomic DNA was removed and RNA was reverse
transcribed to cDNA (10 ng RNA/µL) using the QuantiTect Reverse Transcription Kit
(Qiagen, 205313). Pre-validated primers for mouse GAPDH (Gapdh), sarcomeric αactinin (Actn2), cardiac troponin T (Tnnt2), connexin 43 (Cx43), Nanog (Nanog), and
CD31 (Cd31) transcripts were obtained from Qiagen (Quantitect Primer Assay). cDNA
was amplified in triplicate reactions using Quantitect SYBR Green PCR Kit (Qiagen)
following manufacturer’s instructions. Expression levels were normalized to GAPDH
and then to the 2D PEG control condition by the 2!∆∆!! method (268).
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4.3.4 Scaffold remodeling assay
Images of scaffolds were taken by brightfield microscopy (2x objective, IX70,
Olympus) using a Magnafire camera (Optronics). For scaffolds larger than the field of
view, multiple images were stitched using Adobe Photoshop. Scaffold diameters were
measured using ImageJ (National Institutes of Health) (4 equally spaced diameters were
averaged for each scaffold). Average diameters for each day were then normalized to the
diameter from the day of seeding.

4.3.5 Immunofluorescence and image processing
Sarcomeric α-actinin expression within reprogrammed scaffolds was analyzed by
quantitative immunofluorescence. Day 18 scaffolds were fixed in 3.7% formaldehyde for
45 min at room temperature, treated with 30% sucrose solution for 3.5 h at room
temperature for cryoprotection, then frozen in OCT (Tissue-Tek®, Sakura) at -80º C for
30 min (or more for storage). Scaffolds were cryostat sectioned with careful attention to
depth of sectioning. After sectioning, slides were blocked for 30 min at room
temperature using 10% normal goat serum/1% bovine serum albumin in PBS (also
containing 0.1% Triton-X 100 for permeabilization). Sarcomeric α-actinin primary
antibody (mouse IgG, Sigma A7811) was diluted 1:1600 in the blocking solution and
applied to the slides overnight at 4ºC. Slides were washed 3x in PBS (5 min each) before
incubation in secondary antibody diluted 1:1000 in blocking solution (1 h at room
temperature, Alexa Fluor 594 goat anti-mouse, Invitrogen, A-11005). Slides were
washed 3x in PBS before application of DAPI as a nuclear counterstain (100 ng/mL, 30
min at room temperature). Slides were washed once more and coverslips were applied.
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For quantification of sarcomeric α-actinin expression, images were acquired by
fluorescence microscopy (IX70, Olympus) using a Magnafire camera (Optronics). Each
section was imaged in its entirety using a 10x objective. Images were analyzed in Matlab,
with the number of α-actinin positive pixels normalized to the number of DAPI positive
pixels for each image to create an α-actinin-DAPI ratio. Ratios were then averaged with
respect to condition or depth within the scaffold. For the cell density analysis, at least 20
images were averaged per scaffold. For the depth analysis, at least 6 images were
averaged per depth region, per scaffold.

4.3.6 Statistics
Two-condition comparisons were made using student’s t-test, whereas multiple
comparisons were made using ANOVA with post-hoc Tukey HSD. Data are presented as
mean ± standard error of the mean.

4.4 Results
4.4.1 Effects of dimension and 3D scaffold material on gene expression
of directly reprogrammed cells
To assess the effects of dimension and 3D scaffold material on the phenotype of
reprogrammed cells, we tested three 3D conditions and normalized gene expression to
cells cultured on 2D PEG-lam(5x)-RGD(5x) substrates (300). Microspheres used in
scaffolds within this experiment were also PEG-lam(5x)-RGD(5x) (2:1 OVs:OAm).
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Cardiac troponin T (Tnnt2) and sarcomeric α-actinin (Actn2) are well-established
cardiomyocyte markers, while connexin 43 (Cx43) is a gap junction protein that is
present in ventricular cardiomyocytes and many other cell types (including ESCs (302)).
Nanog (Nanog) is a pluripotent cell marker, which is minimally expressed by cells
directly reprogrammed on 2D PEG-lam(5x)substrates (~700-fold lower than RW.4

Figure 4.2: Effects of dimension and 3D scaffold material on gene expression. Expression of cardiac
markers Actn2, Tnnt2, and Cx43, pluripotency marker Nanog, and endothelial cell marker Cd31 was
assessed for various 3D materials (100% PEG- green columns, collagen/PEG hybrid- red columns,
100% collagen I- blue columns) and normalized to levels from 2D PEG culture substrates (with
laminin and 5 mM RGD) by the 2-ΔΔCt method. PEG microspheres used in 3D materials were also
functionalized with laminin and 5 mM RGD. Gene expression was compared using a nonparametric
Kruskal-Wallis test with post-hoc Tukey HSD. The collagen/PEG hybrid material presented no
statistical differences for any gene compared to the 2D control. However, expression of cardiac
markers Actn2 and Tnnt2 was downregulated for the 3D 100% PEG microsphere and 100% collagen
I scaffold conditions (*p<0.05). Cx43 expression was slightly upregulated for all conditions,
possibly due to the presence of other cell types (#p<0.05 between 100% PEG-microsphere and 100%
collagen I). Nanog expression was not significantly different for any of the tested conditions. Cd31
expression was downregulated in the 100% PEG microsphere scaffolds compared to the 2D control
(*p<0.05), but changes in the collagen and collagen/PEG hybrid were not significant.
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mouse ESCs (300)). Since the originally described protocol reported a progenitor that
may have potential to form vascular cell types as well as cardiomyocytes (84), we also
looked at the endothelial cell marker CD31 (Cd31).
Compared to the 2D PEG control, cardiac markers Actn2 and Tnnt2 were
downregulated for the 100% PEG-microsphere and 100% collagen 3D scaffold
conditions (Fig. 6). Cardiac gene expression from the 3D PEG/collagen hybrid scaffold
did not differ statistically from the 2D control (though a 9.3-fold decrease in the mean
was observed). Cx43 levels were slightly higher in 3D materials than in 2D, but this was
not statistically significant. Cx43 upregulation in conjunction of downregulation of the
more specific cardiac genes may reflect reprogramming into other cell types (for example,
Cx43 is also expressed in ESCs (302)). For all 3D materials, Nanog expression remained
similar to the 2D control. Cd31 was significantly downregulated for 100% PEG
microsphere scaffolds but not for the 100% collagen or the collagen/PEG hybrid scaffold,
suggesting these materials may be better suited for endothelial cell differentiation or
certain hematopoietically derived cell types (neutrophils, platelets, monocytes, and some
T-cells) that also express Cd31 (303).
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4.4.2 Effects of cellular remodeling on 3D direct reprogramming to
cardiomyocytes
In two dimensions, reprogramming cells begin to form clusters around day 10,
and many of these begin beating by day 18. These clusters are often macroscopically
visible, and can grow to be several millimeters wide (Fig. 4.3 a, (84, 300)). In 3D culture,

Figure 4.3: Morphology of reprogrammed cells at scaffold surfaces compared to cells embedded
within microspheres. Scaffolds were fixed at day 18, sectioned, and stained for sarcomeric α-actinin.
A) On 2D substrates, reprogrammed cells form large clusters that may be several millimeters wide
and sometimes beat spontaneously. B) Densely packed, large, beating clusters were occasionally
seen on the surfaces of scaffolds. Sarcomeric α-actinin within these surface clusters had a striated
appearance, indicating a mature contractile apparatus (white arrow in magnified inset). C) The
largest cluster of α-actinin positive cells embedded within microspheres at a depth greater than 100
µm. α-actinin positive clusters within microspheres were rare and smallerthan those on the surface.
Most often, α-actinin positive cells occurred in groups of 1-3 cells if embedded within microspheres.
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beating clusters were occasionally observed at scaffold edges, and these stained positive
for large areas of striated sarcomeric α-actinin (Fig. 4.3 b). However, at greater depths,
α-actinin positive cells almost always appeared in small groups of 1-3 cells (not shown).
The largest α-actinin positive cluster observed surrounded by microspheres was ~100 µm
wide (Fig. 4.3 c), but this was unusual and very small compared to beating clusters seen
on 2D substrates. The decrease in reprogramming efficiency seen in the PEG materials
may be partially attributed to the inability to form large clusters, as is seen in studies on
embryoid bodies (285, 304-307). This would impact paracrine signaling and possibly
interfere with reprogramming.
Cells release matrix metalloproteinases (MMPs) that cleave and remodel collagen

Figure 4.4: Cellular remodeling of 3D scaffolds. Decreasing scaffold diameter indicates ECM
cleavage and remodeling. Scaffolds were fabricated 1 day prior to initiating reprogramming and
their diameters were measured over the first 5 reprogramming days. Diameters were normalized
to their diameter at day 0. All groups decreased in diameter, with collagen-containing scaffolds
decreasing to a greater extent than 100% PEG microsphere scaffolds (*p<0.05 by ANOVA with
post-hoc Tukey HSD). This indicates that cells are better able to remodel the collagen materials
than the PEG microspheres.
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gels, causing a decrease in the scaffold size over time (301, 308, 309). To highlight the
differences in how reprogramming cells may react with scaffold materials, we took
scaffold diameter measurements during the early stage of direct reprogramming (Fig. 4.4).
Microspheres used in this experiment were PEG-lam(5x)-RGD(5x) (2:1 OVs:OAm). All
scaffolds showed decreases in diameter, but the collagen-based scaffolds shrank much
more than PEG microsphere scaffolds. This could be due in part to the greater
susceptibility to MMP cleavage (p<0.05 by ANOVA with post-hoc Tukey HSD test at
every day following seeding).
PEG microsphere morphology was retained throughout reprogramming in 100%
PEG scaffolds, but few sphere-like PEG structures were found in collagen-PEG hybrid
scaffolds after 18 days of reprogramming (Fig. 4.5). In Fig. 4.5, PEG in collagen-hybrid
scaffolds was fluorescently labeled (red), whereas the PEG microspheres in 100%
microsphere scaffolds were visible by phase microscopy. In the collagen/PEG hybrid
scaffold, embedding PEG microspheres in the collagen gel enables a reaction between
free PEG-VS groups and the surrounding collagen fibrils, such that the PEG microsphere
becomes part of the polymer network. The cells, which use focal adhesions to reshape
the collagen, are also pulling on the collagen-linked PEG. In the 100% PEG microsphere
scaffolds, cells interact only with laminin or RGD-functionalized VS groups, which
likely provides far fewer focal adhesions than the collagen/PEG hybrid scaffold. This
may explain why the 100% PEG microsphere scaffolds decrease to a lesser extent than
the collagen based materials. In addition to differences in the chemical structure of the
scaffold materials, the differences in cellular interactions with the materials may help to
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explain the trend towards more efficient cardiac reprogramming seen in the in collagenbased scaffolds (Fig. 4.2).

4.4.3 Effects of cell density and cell depth on 3D direct reprogramming
to cardiomyocytes
To assess the possible effects of nutrient diffusion and cell density within the

Figure 4.5: Morphology of PEG in scaffolds with or without collagen after 18 days of reprogramming.
Collagen-PEG hybrid scaffolds were fabricated with fluorescent PEG microspheres (red, left side).
Microspheres in 100% PEG scaffolds (right side) were not fluorescent, but are clearly visible by phase
contrast. Scaffolds were fixed on day 18, sectioned and imaged by either fluorescence or phase
microscopy. By day 18, the PEG in collagen-PEG hybrid scaffolds no longer resembled microspheres,
indicating that it had been remodeled by cells. Microspheres were still clearly defined in 100% PEG
scaffold (lower right, white arrows).
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scaffold, we assessed sarcomeric α-actinin expression by immunohistochemistry at
various depths from the surface of PEG-RGD(1x) microsphere scaffolds (1:1 OVs:OAm).
Scaffolds were seeded at either 5 million (low density) or 25 million (high
density) MEFs/mL. The seeding density had an inverse effect on reprogramming
efficiency, with α-actinin:DAPI ratios for low cell density scaffolds 18.7-fold higher than
high cell density scaffolds (p<0.05 by t-test) (Fig. 4.6 a). Similar results have been noted
in iPSC derivation from MEFs using the inducible transgene system (310), and may
reflect: 1) differences in paracrine signaling intensity, or 2) nutrient depletion at high cell
densities. The effect of depth into the scaffold was less pronounced, but a decreasing
trend in reprogramming efficiency was noted as depth increased (Fig. 4.6 b). When
depths were normalized to the outermost region, the innermost region had a 1.62 fold
decrease in the α-actinin/DAPI ratio as compared to the outermost region (Fig. 4.6 c)
(p<0.05 by t-test). This could be attributed to multiple effects: 1) limitations in cluster
size as mentioned above, or 2) lowered diffusion of nutrients.
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Figure 4.6: Effects of cell density and cell depth on direct reprogramming. A quantitative
immunohistochemical analysis of sarcomeric α-actinin expression was performed to analyze
expression at various depths within PEG microsphere scaffolds initially seeded at two different cell
densities (5 million/mL- light green columns and 25 million/mL- dark green columns). Scaffolds were
fixed on day 18, sectioned and stained for the α-actinin and DAPI. Fluorescent images were
analyzed in Matlab, with the number of α-actinin positive pixels normalized to the number of DAPI
positive pixels for each image. A) Cell seeding density was inversely related to reprogramming
efficiency (*p<0.05 by t-test), with a 5-fold increase in cell density resulting in an 18.7-fold decrease
in α-actinin/DAPI ratio (n=3, >20 images analyzed per condition). B) Reprogramming was
generally higher in the outer regions of the scaffold, though no statistical differences were seen (n =
2-3, >6 images analyzed per condition). C) Data from scaffolds of both cell densities were
combined and the 151-300 and 301-450 depths were normalized to the outermost region to present
the fold decrease in α-actinin/DAPI ratio. The ratio of the innermost region was 1.62-fold lower
than the outermost region (*p<0.05 by t-test, n = 4-5, >12 images analyzed per condition).
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4.4.4 Effects of substrate topography on direct reprogramming to
cardiomyocytes
To investigate the effects of substrate topography while eliminating the variable
of diffusion, we reprogrammed cells on a 2D layer of PEG-Mat(1x)-RGD(1x)
microspheres (1:1 OVs:OAm), and normalized their gene expression to flat 2D PEGlam(1x). In our previous study, reprogramming efficiency remained similar between
these adhesion molecules at these concentrations (300), so we expect any changes to be
more influenced by the variation in topography. Changes in mechanical stiffness of the
culture substrate can have dramatic effects on cellular phenotype (108, 109). The flat,
hydrated PEG gel is estimated to be 1.1 millimeters thick, while the microspheres are
about 10.2 ± 0.2 µm thick (~100-fold thinner). Therefore, the relative stiffness
experienced by the cells is likely much higher on the microsphere layer (closer to that of
the TCPS substrate underneath). To demonstrate that variations from the flat PEG
surface are not solely attributed to these mechanical differences, we also have included
the gene expression data for TCPS-lam(1x). Culture on the PEG-microsphere layer
caused dramatic decreases in Actn2 (21.2 ± 11.2-fold), Tnnt2 (5.0 ± 2.4-fold), and Cd31
(27.0 ± 4.4-fold) expression as compared to the 2D PEG gel surface (p<0.05 by t-test)
(Fig. 4.7). These changes were more pronounced than variations between PEG-lam(1x)
and TCPS-lam(1x), indicating that they were not solely attributable to mechanical
variation. This finding also suggests that, in addition to diffusion limitations, the
microsphere topography is not optimal for direct reprogramming to the cardiomyocyte
phenotype as markers were downregulated despite unrestricted access to the media.
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Figure 4.7: Effects of 2D PEG topography on gene expression of directly reprogrammed cells. In
order to analyze responses to microsphere topography without the confounding effects of diffusion
limitations seen in 3D, cells were reprogrammed on a thin layer of PEG microspheres at the bottom
of a 2D well, and expression levels were normalized to a flat 2D PEG gel control condition. Cells on
the thin layer of microspheres experience higher stiffness than those on the thicker flat PEG gel due
to closer proximity to the TCPS surface underneath (~100 fold difference in gel thickness). Because
of this, expression levels from TCPS were also included to help delineate effects of topography and
mechanical properties. Expression of cardiac markers Actn2 and Tnnt2 were downregulated on the
microsphere layer as compared to the 2D PEG gel (*p<0.05 compared to the 2D PEG control by ttest). Nanog was upregulated (*p<0.05), but still low in comparison to RW.4 mouse embryonic stem
cells (not shown). Cd31 was also downregulated on the microsphere layer, indicating that the
topography may be disruptive for formation of endothelial cells. Regulation patterns between the
microsphere layer and the TCPS substrate varied (#p<0.05 for 2D microsphere layer versus TCPS),
suggesting that expression differences between the thin layer of microspheres and the thick flat PEG
gel cannot be solely attributed to mechanical differences.
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4.5 Discussion
The role of the microenvironment on embryonic cells has been under
investigation for nearly a century, when their orientation along a fiber was first described
(4). Since then, we have become increasingly aware of the roles of cellular remodeling,
diffusion, intercellular contacts, topography, and mechanical properties in embryonic
development and stem cell differentiation protocols. Differentiating cells in 3D culture is
an increasingly important goal for the field of regenerative medicine, as cell
transplantation techniques will require vastly higher numbers of cells than 2D culture can
practically provide.
The improved scalability of 3D culture systems can be leveraged to meet this
demand. For example, in this study we cultured 200,000 cells in one collagen-based
scaffold, using 3 mL of media per day. Culturing the equivalent number of cells in 2D
required 28 mL/day (~10 times as many cells in 3D versus 2D per mL of media). While
our initial studies show a modest decrease in cardiac gene expression in 3D for the
collagen-based scaffolds (Fig. 4.2), the 3D culture may still yield more cardiomyocytes
per mL of media. Furthermore, various modifications to the material could foreseeably
improve efficiency, and they will be discussed herein. A review of the current cardiac
direct reprogramming literature is beyond the scope of this discussion, but can be found
elsewhere (300).
Our study highlights differences in ECM remodeling between collagen-based and
100% PEG-microsphere scaffolds. Collagen allows the cells to arrange their
microenvironment, as demonstrated by the scaffold size changes (Fig. 4.4) and the
differences in the day 18 PEG morphology when microspheres were embedded in
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collagen versus part of a 100% microsphere scaffold (Fig. 4.5). Other studies have also
highlighted the importance of remodeling in 3D environments. Recently, our
collaborators showed greater PC12 cell aggregation in collagen-PEG microsphere hybrid
scaffolds compared to 100% PEG microsphere scaffolds (311). The Seliktar group has
studied neonatal rat cardiomyocytes cultured in PEG-fibrinogen hybrid materials and
found that increasing the ratio of PEG to fibrinogen limited cellular remodeling (312) and
resulted in a decrease in beating scaffolds (313). Similarly, the Hubbell group has found
that inhibiting remodeling activity within a bulk PEG hydrogel caused P19 cells
undergoing cardiac differentiation to stall at a progenitor state, whereas their uninhibited
counterparts expressed markers of fully mature cardiomyocytes (159). It is therefore
likely that remodeling constrictions within our 100% PEG microsphere scaffolds were
partially responsible for the dramatic downregulation of cardiac gene expression
compared to 2D surfaces.
Though they rarely exhibit a pluripotent phenotype (84), reprogramming cells on
2D surfaces form large clusters that morphologically resemble embryoid bodies (EBs).
These clusters are macroscopically visible and can sometimes be several millimeters
wide (Fig. 4.3 a). Several groups have demonstrated profound effects of EB size on
cardiac differentiation efficiency (304-307). In 1987, Smith et al. noted that cardiac
differentiation from P19 embryonic carcinoma cells was dependent on the initial size of
the cell aggregates. They suggested a relationship between paracrine signals from an
endodermal layer on the aggregate surface and ultimate cardiac differentiation efficiency
(304). More recently, the Zandstra group has also noted that the optimal EB size for
cardiac differentiation is 400 µm (as compared to 200 or 800) (285, 305). They
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confirmed the relationship between cardiac differentiation and the endodermal surface
layer, linking EB size to the relative strength of paracrine signaling (314). Taking these
studies into account, it is possible that the relatively small pore size in our 100% PEG
microsphere scaffolds (266) inhibited the large cluster formation seen in 2D and
interfered with cardiac direct reprogramming processes.
We investigated the impact of topography on direct reprogramming by comparing
gene expression from cells cultured on a 2D layer of PEG microspheres, a flat 2D PEG
substrate, or a 2D TCPS substrate (Fig. 4.7). Substrate topographies are well known to
have effects on cellular behaviors (103). For 2D cardiomyocyte culture, particular
research emphasis has been placed on topographies that induce cellular alignment, as is
seen in vivo. In natural myocardium, action potential propagation occurs fastest along the
longitudinal axis of the rod shaped cardiomyocytes (315). The largest collagen fibrils run
parallel to the long axis (316), likely helping cells to maintain their orientation (106). In
2D cardiac culture, elongated topographical features, such as physical fibers (10),
grooves (9), or patterned lines of ECM molecules (317, 318), help to induce cellular
alignment and conduction anisotropy (319). Recently, Levchenko and colleagues
demonstrated that nanoscale variations in elongated 2D surface patterns influence
cytoskeletal architecture and the resulting conduction speed and anisotropy (106). This
research has also been translated to 3D, resulting in greater cellular alignment (227, 320),
anisotropic conduction (321), and higher instances of beating within scaffolds (322). In
contrast to elongated contact cues, the rounded surface of the microspheres does not
appear to be favorable for efficient direct reprogramming to cardiomyocytes. This may
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also further help to explain the better performance of the fibrillar collagen-based
materials as compared to the 100% PEG-microsphere scaffolds (Fig. 4.2).
Many groups have noted a decrease in cell viability and differences in phenotype
at scaffold depths greater than 200 µm due to decreased diffusion of nutrients (177-179).
Depth within EBs also affects cardiac differentiation and cell necrosis (304). Future
studies will need to address this facet of 3D reprogramming, possibly by using smaller
scaffolds or improving nutrient transport using perfusion or hydrodynamic mixing. PEG
microspheres may also improve diffusion within scaffolds made of more fibrous
materials (like collagen or other naturally derived ECM). In a study comparing
chondrogenic differentiation in ECM pellet cultures with and without microspheres, our
collaborators found that inclusion of PEG microspheres reduced the incidence of a
fibrous layer surrounding the pellet culture, and noted several variations in gene
expression patterns (323). Since inclusion of PEG microspheres did not significantly
hinder ECM remodeling in collagen scaffolds (Figs. 4.4 and 4.5) or alter gene expression
(Fig. 4.2), they may be useful for delivering morphogen from within the scaffold. This
has been shown to improve differentiation within EBs by more evenly distributing the
delivery profile (324).

4.6 Conclusion
Future cell transplantation procedures will require more scalable approaches to
stem cell differentiation and direct reprogramming. In this study, we investigated the
effects of several factors on direct reprogramming to cardiomyocytes in 3D cultures. We
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confirmed that material topography, diffusion, and cell density directly impact
reprogramming efficiency in 3D. Our results also suggest that ECM remodeling must be
taken into consideration when designing these 3D scaffolds. The results presented here
lay the groundwork for development of materials that will promote efficient 3D direct
reprogramming.
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CHAPTER 5
Conclusions and Future Directions
In this dissertation, I have explored PEG materials as they relate to cardiac tissue
engineering, first as scaffolds for engineering a cardiac construct (Chapter 2), then as a
base material for designing the stem cell niche (Chapters 3 and 4). In chapter 2, I
designed a novel method for crosslinking PEG microspheres around cells to form a
scaffold that could be easily handled and subjected to robust analyses. To verify that
cardiac cell types would respond well to this material, we encapsulated HL-1
cardiomyocytes, which proliferated and maintained their phenotype over several weeks in
culture. While the gap junction staining suggested that HL-1 cells were connected in
small clusters, large-scale electrical synchrony was not observed within the scaffold.
Certain improvements to the design and protocol may help to promote better organization
and cellular alignment within the scaffold. Primarily, providing matrix-metalloproteinase
degradable sites within the PEG mesh may enable better remodeling and allow for more
cell-to-cell contact (159). Alternatively, the microspheres could be embedded around
cells in a naturally derived hydrogel such as collagen or fibrin, similar to the collagenPEG hybrids described in Chapter 4. This would retain the potential for drug release
from PEG (200) and potentially improve diffusion within the natural hydrogel (167).
Finally, electrical and mechanical stimulation might be helpful for coaxing cells into
cardiac-like organization (230, 247).
The third chapter focused on a new cell type. The HL-1s provided an excellent
model for preliminary biomaterial testing because they skirt many technical issues
encountered with stem cell derived cardiomyocytes. However, their clinical relevance is
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limited because they are a permanently dividing line. We were finishing the HL-1
studies when a new way of considering cell sourcing was emerging. Of the direct
reprogramming strategies published, neither had yet considered the effects of the culture
substrate on efficiency (75, 84). However, from pluripotent cell studies, we know this to
be an important variable that can be engineered to our advantage (100, 124). The protein
resistant properties of PEG ensure a clean slate for delivering the desired bioactive
molecules while inhibiting non-specific adsorption (325, 326). An advantage of one of
the direct reprogramming strategies was the potential to form vascular cells alongside
cardiomyocytes (84, 85). Many in vitro and in vivo studies have also reported the
positive influence of vascular cell types on cardiomyocyte viability (88) and cardiac
function (89, 90) after implantation.
Using custom-engineered 2D PEG substrates, we demonstrated that
reprogramming efficiency could be improved in ways that TCPS substrates would not
allow. We also found RGD to promote proliferation during reprogramming, which
ultimately provided more cardiomyocytes without diminishing efficiency. Interestingly,
the Matrigel proteins that had been used with TCPS in the original publication were
found to have high batch-to-batch variation in the ability to promote cell adhesion to PEG.
Laminin was chosen as a potential alternative because its receptors are known to be
upregulated during the first few days of reprogramming (253), and it makes up ~60% of
the proteins in Matrigel (according to product literature). Because laminin can be
recombinantly synthesized, this also represents a move away from animal derived
materials and toward fully synthetic materials (though for our purposes we did use
purified mouse-derived laminin-1).
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While many questions could still be addressed using the 2D PEG substrates
(differentiation to vascular cells, the effects of substrate elastic modulus, etc.), we were
equally eager to analyze the effects of 3D culture during the direct reprogramming
protocol (Chapter 4). This area of research has 2 main motivations. The first is
scalability; 2D differentiation methods cannot reasonably provide enough cells. For
example, in a recent clinical trial of human MSC injections, the authors injected 205 x
106 bone marrow cells (125). At a typical MSC culture density of 10,000 cells/cm2 (327),
that would require 20,500 cm2, or ~270 typical T75 tissue culture flasks (for just one
patient). While researchers may opt for large, thin, stackable 2D surfaces (“Cell
Factories” with 636 cm2 surface area per plate can be purchased from Thermo
Scientific®) (328), the sheer media volume necessary brings up costs and routine upkeep
becomes labor intensive. As discussed in Chapter 4, optimization of 3D differentiation
methods could help with scalability issues.
The second motivation for Chapter 4 was to determine the effects of 3D culture
on reprogramming efficiency. Since cells typically reside in a 3D environment, they are
accustomed to receiving signals from three dimensions (116). In many cases, they take
on different phenotypes in 2D versus 3D (119, 120), sometimes resulting in improved
differentiation (121-124). Unfortunately, in our study we did not see an improvement in
reprogramming efficiency. However, we did learn important details about how the
reprogramming cells react to microsphere topography, encapsulation between
microspheres, diffusion limitations, and variations in materials (collagen to PEG) that can
help us to design better scaffolds for future studies.

108

In a broader sense, there are many future directions to this project. First, the
direct reprogramming field moves at a rapid pace. Very recently (March of 2013), the
first group published a protocol for directly reprogramming human cells to
cardiomyocytes (83). We will need to consider the clinical relevance of continuing to
work with mouse cell types in future materials studies. Secondly, a study of
simultaneous reprogramming to vascular cells would be highly desirable as it may help
with cardiomyocyte organization within the scaffold (88). For the 3D approaches,
designing enzymatically degradable PEG microspheres may improve remodeling and
organization within the scaffold, which may in turn improve reprogramming efficiency.
The collagen gels containing PEG microspheres may be the most promising of the
three materials investigated in Chapter 4, based on the gene expression studies. Loading
microspheres with bioactive factors may counteract diffusion limitations to improve
reprogramming efficiency. Using microspheres to deliver retinoic acid from within EBs
has shown to advance differentiation, likely by ensuring an even delivery profile instead
of relying on diffusion from the outer surfaces (324). In the Efe et al. protocol, the
pluripotency inhibitor is delivered for 9 days immediately following cell seeding. If we
were to continue using this reprogramming protocol, one might design microspheres to
incorporate controlled release of this or other factors.
Ultimately, diffusion limitations will need to be addressed by either incorporating
perfusion or rotary culture into the methods, or making much smaller 3D constructs
(~200-400 µm wide to completely avoid diffusion issues (177-179)). One such way
would be to fabricate the scaffold as described, then to break it into smaller pieces such
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that the cells were still encapsulated. In fact, such a strategy might lend itself well to in
vivo injections that deliver cells, bioactive factors and surfaces to prevent cell anoikis.
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